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Abstract 
A delivery system is essential to protect the DNA from degradation because of the 
extracellular and intracellular barriers. Two main types of delivery systems have been used to 
deliver genes into the body: viral and non-viral vectors. Although viral vectors are still 
superior over non-viral vectors, non-viral types are a better and safer alternative due to the 
safety concern of viral vectors. The low transfection efficiency of non-viral vectors remains a 
challenge due to the barriers that must be tackled. An effective non-viral vector must fulfill 
many conditions in order to be able to handle these barriers. The vector should be 
biocompatible, biodegradable, able to interact with DNA and cell membrane, able to 
successfully escape the endosome, and finally, capable of entering the nucleus to express the 
required protein. Cationic polymers are one of the most effective non-viral delivery systems. 
Cationic polymer/DNA (also called polyplexes) are able to interact with the DNA through 
electrostatic interaction, which results in DNA complexation and condensation. Gelatin is a 
natural polymer that can be easily modified by increasing the positive charge to effectively 
interact with the DNA and the cell membrane. In this project, gelatin nanoparticles were 
prepared using the two-step desolvation method, and were modified with cholamine as a 
cationic agent. Pluronic block copolymers were subsequently added to protect the cationic 
gelatin/DNA from degradation, and to increase the circulation time. The interactions of 
gelatin/Pluronic/DNA with the model membranes DPPC-CHOL and POPC-CHOL were 
studied using Langmuir’s monolayer study, as well as Brewster’s angle microscopy at the 
air/water interface. Transfection efficiency and cell viability were then evaluated at COS-7 
cells. The results revealed that gelatin nanoparticles were successfully modified, at which 
  v 
point the positive charge increased from +11 to +32. Additionally, cationic gelatin (CG) was 
able to interact with and neutralize the negative charge of the DNA. CG/Pluronic/DNA 
complexes was characterized by size and zeta potential, showing a small particle size and a 
positive charge. The interaction of CG/Pluronic/DNA complex with the model membranes 
demonstrated a fluidization effect, especially with CG and Pluronics, whereas DNA showed 
an ineffective and negligible condensation effect. With respect to transfection efficiency, CG 
results were poor compared to positive control jetPEI®, with no improvement after adding 
Pluronics. Gemini surfactant (GS) was also used in the transfection experiments in hope that 
it might improve the transfection efficiency of cationic gelatin. However, CG/GS showed 
some aggregation, and the positive charge decreased by increasing the CG, which resulted in 
lower transfection efficiency. Cell viability of the cells containing cationic gelatin was very 
high (similar to non-treated cells), which was confirmed by the safety of the gelatin, even 
after modification. More investigational studies and optimizations are required to understand 
the low transfection efficiency of cationic gelatin. These studies will help design more 
effective delivery vectors, either with gelatin or with any other non-viral system.  
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Chapter 1 Introduction and Literature Review 
1.1 History and General Introduction to Gene Therapy 
Gene therapy (GT) has received much attention due to its great potential for the treatment of 
both acquired and inherited diseases such as cancer, cystic fibrosis (CF), acquired 
immunodeficiency syndrome (AIDS), X-linked combined immune deficiency (X-linked 
SCID), emphysema, retinitis pigmentosa, sickle cell anemia, hemophilia, Duchenne 
Muscular Dystrophy (DMD), certain some autosomal dominant disorders, vascular disease, 
neurodegenerative disorders, polygenic disorders, inflammatory conditions, and other 
infectious diseases (Stone 2010, Nayerossadat, Maedeh et al. 2012, Keeler, Elmallah et al. 
2017).  According to the US Food and Drug Administration (FDA), gene therapy is defined 
as products “that mediate their effects by transcription and/or translation of transferred 
genetic material and/or by integrating into the host genome and that are administered as 
nucleic acids, viruses, or genetically engineered microorganisms. The products may be used 
to modify cells in vivo or transferred to cells ex vivo prior to administration to the recipient” 
(Wirth, Parker et al. 2013). A gene therapeutic should fulfil two characteristics: (a) it should 
contain an active substance containing or consisting of a recombinant nucleic acid that is 
administered into the nucleus in order to regulate, repair, replace, add, or delete a defective 
gene; (b) its therapeutic, diagnostic, or prophylactic effect should relate to the recombinant 
nucleic acid it contains (Wirth, Parker et al. 2013). When gene therapy is used in the 
treatment of genetic diseases, it restricts these diseases by introducing genes coding for 
functional proteins to cells; thus, it normalizes the cells and even organs in question (Jin, 
Zeng et al. 2014). Gene therapy is also used to produce large quantities of secreted proteins 
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that can be utlized for direct therapeutic applications or vaccine production (Jin, Zeng et al. 
2014).  
Since the first attempt of gene therapy made by Fredrick Griffith in 1928 (Griffith 1928), 
there have been enormous and significant changes have occurred in the development and 
improvement of gene therapy (Figure 1.1-1). The most important change has been the 
development of delivery systems. Deoxyribonucleic acid (DNA) requires a delivery vehicle 
in order to efficiently travel through extra- and intra-cellular barriers, finally entering the 
nucleus to express the required protein to correct or moderate specific diseases. Two main 
types of delivery systems have been developed for the purpose of transferring plasmid DNA 
into the nucleus: viral and non-viral vectors. GendicineTM, developed by SiBiono Gen Tech 
Co. in Shenzhen, is a non-replicative adenovirus used for the treatment of head and neck cell 
squamous carcinoma (HNSCC) that was approved by China's State Food and Drug 
Administration (SFDA) in 2003 as the first gene therapy based product for clinical use (Peng 
2005, Wilson 2005). Two years later, SFDA approved OncorineTM, another gene therapy-
based product. In contrast to GendicineTM , OncorineTM is a replicative adenovirus developed 
by Sunway Biotech Co. Ltd for the treatment of late-stage refractory nasopharyngeal cancer 
in combination with chemotherapy (Liang 2012). To date, the US FDA has not approved any 
gene therapy product. However, Cerepro®, developed by Ark Therapeutics Group plc in 
2009, was the first adenoviral vector gene therapy-based product to complete a phase III 
clinical trial in the European Union (EU)  (Wirth, Samaranayake et al. 2009). Cerepro® is 
intended for use in the treatment of malignant brain tumor. Then, in 2012, the European 
Medicines Agency (EMA) recommended a gene therapy product (Glybera) for approval in 
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the EU for the first time (Wirth, Parker et al. 2013). Glybera, developed by Amsterdam 
Molecular Therapeutics, is an adeno-associated viral vector engineered to express 
lipoprotein lipase to treat severe lipoprotein lipase deficiency. Lastly, Strimvelis, another 
gene therapy product, was approved in Europe for the treatment of ADA-SCID (severe 
combined immunodeficiency due to adenosine deaminase deficiency) in May 2016 
(Keeler, Elmallah et al. 2017, Touchot and Flume 2017). Strimvelis, which is the first ex 
vivo stem cell gene therapy developed by GlaxoSmithKline in collaboration with a 
charitable organization (Italian’s Fondazione Telethon) and an academic center  in Milan  
(Ospedale San Raffaele). These new approvals and recommendations along with a high 
number of ongoing clinical trials (Figure 1.1-2) have effectively demonstrated the enormous 
potential effectiveness of gene therapy; thus, it is very likely that gene therapy will find its 
place among clinical therapeutics.  
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   Reproduced with permission from (Wirth, Parker et al. 2013) 
* Reproduced from (Keeler, Elmallah et al. 2017, Touchot and Flume 2017) 
 
1.2 Classifications of Gene Therapy Delivery Systems 
1.2.1 Viral vectors 
Viral vectors involve the packaging of DNA into a virus particle. Gene transfer occurs by 
normal viral infection (mechanisms) and is both efficient and cell selective. There are 
currently more than 1700 approved gene therapy clinical trials that utilize viruses as vectors 
for either gene therapy or vaccines applications (Figure 1.2-1) 
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Figure 1.1-1: Timeline highlighting some significant milestones of gene therapy 
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Figure 1.2-1: Vectors used in gene therapy clinical trials (wiley.co.uk) 
 
With their distinct biological keys (e.g., glycoprotein in a viral envelope (Grandi, Spear et al. 
2004)), viruses are able to infect cells and cross both the cell membrane and nuclear barrier 
via a rapid cytosolic passage along dynein-based active linear translocation microtubules (De 
Laporte, Rea et al. 2006). This feature enables viruses to achieve high transfection efficiency 
in most of the transfected cells in vitro. However, several concerns with respect to viral 
vectors have been raised. These include: a strong immune response in host cells due to viral 
protein(s), which causes induction of inflammatory system resulting in degenerating of 
transduced tissues and toxic production; insertional mutagenesis; limitation to the size of 
loaded DNA; and the high cost of production. With respect to insertional mutagenesis, an 
ectopic chromosomal integration of viral DNA may cause malignant transformation due to 
the disruption of the expression of tumor suppression or due to the oncogene activation 
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(Ramamoorth and Narvekar 2015). In 1999, the tragic death of Jessie Gelsinger, an 18-year-
old patient who was being treating for ornithine transcarbamylase (OTC) (Stolberg 1999) 
with an adenovirus vector, as well as the two out of eleven children who were developing a 
blood disorder similar to leukemia following adenoviral treatment against SCID, placed viral 
vectors under severe inspection and led researchers to explore alternative, safer vectors that 
can replace viruses (Teichler Zallen 2000). Adenovirus (Ad), retrovirus, adeno-associated 
virus (AAV), lentivirus, herpes simplex virus, and poxvirus are the most common viruses 
used in clinical trials as delivery systems for gene therapy. Table 1.2-1 summarizes the 
advantages and disadvantages of some of these viruses.  
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Table 1.2-1: The main viruses used as gene delivery systems, with their advantages and 
disadvantages 
Reproduced with permission from (Ratko, Cummings et al. 2003) 
Vector Advantages Disadvantages 
Adenovirus (Ad) Very high titers (1012 pfu/ml) * 
High transduction efficiency in 
vitro and in vivo 
Transduction many cell types 
Transduces proliferation and 
nonproliferating cells 
Production easy at high titers 
 
Remain episomal 
Transient expression 
Requires packaging cell line 
Immune-related toxicity with 
repeated administration 
Potential replication complex 
No targeting 
Limited insert size: 4-5 kb 
Adeno-associated Virus (AAV) Integration on human chromosome 
19 to establish latent infection 
Transduction does not require cell 
division 
Small genome, no viral genes 
 
No well characterized 
No targeting 
Requires packaging cell line 
Potential insertional mutagenesis 
High titers (1010 pfu/ml) but 
Production difficult 
Limited insert size: 5 kb 
Herpes Simplex Virus Large insert size 
Neuronal tropism 
Latency expression  
Efficient transduction in vivo 
Replicative vectors available 
Cytotoxic 
No targeting 
Requires packaging cell line 
Transient expression does not 
integrate into genome  
Moderate titers (104-108 pfu/ml)  
Lentivirus Transduction proliferating and 
nonproliferating cells Transduces 
hematopoietic stem cells 
Prolonged expression  
Relatively high titers (106-107 
pfu/ml) 
Safety concern: from human 
immunodeficiency virus origin 
Difficult to manufacture and store  
Limited insert size: 8 kb 
Clinical experience limited 
Retrovirus Integration into cellular genome  
Broad cell tropism 
Prolonged stable expression 
Require cell division for 
transduction 
Relatively high titers (106-107 
pfu/ml) 
Large insert size: 9-12 kb 
 
Inefficient transduction 
Insertional mutagenesis 
Requires packaging cell line 
Requires cell division for 
transduction  
No targeting 
Potential replication competence   
*Plaque-forming unit (PFU): a measure of the number of particles capable of forming plaques per 
unit volume, such as virus particles. 
1.2.2 Non-viral vectors 
Due to the large number of clinical trials using viral vectors that have failed for safety 
reasons (or for failure to meet clinical endpoints), non-viral vectors are viewed as an 
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appropriate alternative method. Non-viral vectors are divided into three methods: naked 
DNA, physical based and chemical based. Examples of physical methods includes 
electroporation, gene gun, sonoporation, photoporation, and magnetofection while chemical 
methods include cationic lipids and cationic polymers. Non-viral vectors are safe (generally 
non-toxic, and non-immunogenic), easy to produce in large scale, cheap, and able to deliver 
large pieces of DNA in contrast to viral vectors (Li and Huang 2007) (Table 1.2-2). However, 
non-viral vectors demonstrate low transfection efficiency compared to viral vectors because 
of the numerous extra- and intra-cellular obstacles required to be crossed before reaching the 
nucleus to express the necessary protein (Pathak, Patnaik et al. 2009).  
Table 1.2-2: Comparison between viral and non-viral vectors (Li and Huang 2007) 
Viral vectors Non-viral vectors 
High production cost Low production cost 
Immunogenic Low immunogenicity 
Limitation in size loaded of DNA Easily produced in large scale 
Potential for oncogenesis Very low toxicity  
High transfection efficiency Low transfection efficiency  
 
1.3 Barriers Facing Non-viral Gene Delivery  
Nucleic acids (DNA or RNA) must cross several barriers before they are reaching the 
nucleus and expressing the required protein. These barriers can be divided into extracellular 
and intracellular barriers. Extracellular barriers include skin, blood cells, plasma components, 
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the reticuloendothelial system (RES), and the immune system response. Intracellular barriers 
include the plasma membrane, endosomes, trafficking with the cytosol, nuclear localization, 
and nuclear membrane (Figure 1.3-1). As a result, several researchers who have studied these 
barriers and have attempted to overcome them by using various techniques. Regardless of the 
method by which non-viral vectors are administered into the body (e.g., inhalation, IV, IM, 
gavage, etc.), they should come to the extracellular environment (Gottfried and Dean 2013). 
There, the vector (either cationic lipid or cationic polymer) may either be degraded or cleared 
rapidly from circulation due to multiple factors existing within the extracellular milieu, such 
as the presence of serum proteins, blood cells, and enzymatic degradation (Gottfried and 
Dean 2013). An effective strategy to overcome these barriers and to protect the DNA from 
degradation is the use of PEGylated polymer. Polyethylene glycol (PEG) has been 
demonstrated to enhance the stability of the complexes in serum and to substantially increase 
the vector’s half-life in the systemic circulation (Crawford 2002, Kaul and Amiji 2002, 
Otsuka, Nagasaki et al. 2003, Kaul and Amiji 2005, Kou, Wang et al. 2014, Ran, Liu et al. 
2014, Jones, Chen et al. 2015).   
The presence of a positive charge is significant, both to interact with the negatively charged 
phosphate group on in the DNA, and also with the negatively charged proteoglycan 
contained in the cell membrane (Halama, Kuliński et al. 2009). The electrostatic interactions 
between plasmid DNA and cationic polymer help by condensing the DNA, and protecting the 
complex from degradation by nucleases (Ogris and Wagner 2002, Halama, Kuliński et al. 
2009). 
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Figure 1.3-1: Schematic presentation of barriers required to be overcome by nucleic acid 
using non-viral vectors 
Reproduced with permission from (Yin, Kanasty et al. 2014) 
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Once the polyplex is taken up by endocytosis, it has to escape from the endosome and travel 
toward the nucleus before it is degraded at the lysosomal level. Cationic polymers achieve 
endosomal escape mainly through a “proton sponge” mechanism. The proton sponge 
hypothesis is that release of the DNA occurs when low pH in the endosomal environment 
results in protonation of the entrapped agents with a high buffering capacity. Protonation 
induces an extensive inflow of ions and water into the endosome. This leads to osmotic 
swelling and rupturing of the endosomal membrane; therefore, releasing of the entrapped 
components (Varkouhi, Scholte et al. 2011). Cationic lipids can escape the endosome by 
destabilizing the endosomal membrane, resulting in a flip-flop reorganization of 
phospholipids, which then dissociate the DNA into the cytoplasm (Xu and Szoka 1996).  
Afterwards, the free nucleic acid must cross the nuclear membrane for transcription and 
expression of the encoded protein.  
The nuclear membrane is considered a major barrier for DNA delivery. Depending on 
the cell type, only 1 to 10% of the transfected DNA can enter the nucleus (Cohen, van der Aa 
et al. 2009, Glover, Leyton et al. 2010). Pollard et al. (Pollard, Remy et al. 1998) stated that 
PEI-DNA polyplexes showed higher transfection efficiency when microinjected in cytoplasm 
compared to naked DNA or DOTAP/DNA lipoplexes. This means that PEI has the ability to 
facilitate DNA translocation into the nucleus (Tros de Ilarduya, Sun et al. 2010). Designing 
non-viral delivery vehicles that overcome these barriers is the primary goal in obtaining 
effective transfection efficiency. Numerous non-viral vectors can be used to deliver DNA, 
mRNA and short double-stranded RNA, including small interfering RNA (siRNA) and 
microRNA (miRNA) mimics. These vectors require to prevent degradation by serum 
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endonucleases and evade immune detection. These objectives can be achieved through 
chemical modifications of the nucleic acids and the encapsulation of vectors. These vectors 
also require avoiding renal clearance from the blood and prevent nonspecific interactions by 
using polyethylene glycol (PEG) or through specific characteristics of particles. In addition, 
these vectors need to extravasate from the bloodstream to reach target tissues, which requires 
certain characteristics of particles and specific ligands. Finally, these vectors require to 
mediate cell entry and endosomal escape by specific ligands and key components of carriers. 
siRNA and miRNA mimics must be loaded into the RNA-induced silencing complex (RISC), 
whereas mRNA must bind to the translational machinery. DNA must be further traveled to 
the nucleus to express the required protein (Yin, Kanasty et al. 2014) (Figure 1.3-1). 
1.4 Naked DNA  
Administration of naked DNA is considered the least difficult strategy for non-viral 
transfection. Although clinical trials completed of intramuscular injection of a naked DNA 
plasmid have had some success, expression has been very low in contrast with different 
strategies for transfection. In addition to trials with plasmids, there have been trials with 
naked polymerase chain reaction (PCR) product, which have had relative or more prominent 
success. This achievement, nonetheless, does not measure up to that of alternate techniques, 
prompting research into more proficient strategies for the conveyance of the naked DNA, for 
example, electroporation and the utilization of a "gene gun", which shoots DNA coated gold 
particles into the cell utilizing high pressure gas. 
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1.5 Physical Methods of Non-viral Systems 
These methods depend on using physical force in order to destabilize the cellular membrane, 
therefore facilitating the entry of gene therapeutic materials into the cells. These methods are 
simple and straightforward.  
1.5.1 Electroporation  
Electroporation is known as gene electro injection, gene electro transfer, electrically 
mediated gene therapy, or electro gene transfer (Ramamoorth and Narvekar 2015). It works 
by applying an electric field greater than the membrane capacitance into the targeted tissue 
cell membrane, resulting in a pore that allows the molecules to pass through it (Figure 1.5-1). 
As a result, the previously injected DNA can enter into the cytoplasm and nucleoplasm of the 
cell (Nayerossadat, Maedeh et al. 2012). This method is very effective and safe when it 
applied in vivo in comparison to other non-viral methods. However, the complexity of 
surgical procedures, and high voltage [>700V/cm] applied to the tissues, as well as the 
difficulty of reaching some internal tissues makes this method inappropriate for delivering 
DNA (Young and Dean 2015).   
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Figure 1.5-1: Basic concept of electroporation. Reproduced from (https://igtrcn.org/ 
injectoporation-for- gene-delivery/) 
 
1.5.2 Gene gun  
The gene gun (also known as particle bombardment, micro projectile gene transfer or 
ballistic DNA - Figure 1.5-2) delivers DNA coated heavy metal particles into the target tissue 
at a particular speed using high voltage electronic discharge, spark discharge, or high 
pressure inert gas, usually helium (Mali 2013). The most common metal particles used in this 
method are gold, tungsten, and silver, which all typically measure 1 µm in diameter. Gene 
transfer is affected by several parameters such as gas pressure, particle size, and dose 
frequency. Precise delivery of DNA is the most important advantage using the gene gun 
method, and it most commonly used in gene therapy that targets ovarian cancer (OC) cells in 
vitro (Ramamoorth and Narvekar 2015).  
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1.5.3 Sonoporation 
Sonoporation is a noninvasive technique using ultrasound wave to permeabilize the cell 
membrane; thus, allowing the uptake of DNA. Genetic materials of interest are first 
administered into the circulation using microbubbles, followed by the application of the 
ultrasound waves. The ultrasound waves cavitate and break up the microbubbles within the 
microcirculation of target tissue, leading to the disruption of the nearby cell membrane that 
results in targeted transfection of the therapeutic gene (Omata, Negishi et al. 2015). The 
major advantages of sonoporation include safety, noninvasiveness, and the ability to reach 
internal organs without the necessity of surgery; consequently, it is used in the brain, cornea, 
kidney, and peritoneal cavity, as well as in muscle and heart tissues (Ter Haar 2007, 
Ramamoorth and Narvekar 2015).  
Reproduced with permission from (Mellott, Forrest et al. 2013) 
Figure 1.5-2: Ballistic Gene Delivery 
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1.5.4 Photoporation  
This technique works by using a single laser pulse in order to generate a pore in the cell 
membrane allowing the DNA to enter into the cells. The effectiveness of this method 
depends on the focal point and pulse frequency of the laser. The major advantage of this 
approach is its safety, in which the pore that is formed by the laser can be healed in less than 
a second. However, the lack of documented evidence limits the use of this technique (Li and 
Huang 2007). 
1.5.5 Magnetofection 
The magnetofection technique is based on coupling therapeutic gene to magnetic 
nanoparticles, which are then introduced into the cell culture (Jones, Chen et al. 2013). The 
field gradient is produced by adding rare, earth electromagnets under the cell culture, which 
then result in increasing transfection speed that arises from increasing the complex 
sedimentation. The therapeutic gene-magnetic particle complex is administered intravenously 
when it used in vivo. With the help of enzymatic cleavage of cross linking molecules, charge 
interaction, or charge degradation, the genetic material is released (Plank, Schillinger et al. 
2003). This method is considered to be an alternative for certain primary cells, as those 
transfections are difficult when using other techniques.  
1.6 Chemical based Non-viral Systems  
Chemical methods of transfection are divided into two categories: inorganic particles (such 
as calcium phosphate, silica, and gold particles); and organic synthetic/natural materials 
(such as cationic lipid and cationic polymers). 
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1.6.1 Inorganic particles  
The most common examples of these particles include calcium phosphate, gold, and silica. 
They have small nanoparticles that are capable of protecting the DNA from degradation and 
avoiding most of the physiological barriers (RES in particular).  
1.6.1.1 Calcium phosphate 
Calcium phosphate particles are biodegradable, biocompatible, non-toxic, and non-
immunogenic (Choi, Cui et al. 2015). Calcium phosphate, as a delivery system, works by co-
precipitating the calcium phosphate and DNA in the aqueous core of the reverse micellar 
droplets (Roy, Mitra et al. 2003). They play a vital role in endocytosis, and they are readily 
absorbed due to their high nucleic acid binding affinity (Ramamoorth and Narvekar 2015, 
Bakan, Kara et al. 2017). About 85% of the added DNA was found in the matrices of calcium 
phosphate nanoparticles (Roy, Mitra et al. 2003). Due to the problem of calcium phosphate 
crystal growth, the presence of magnesium is occasionally required (Ramamoorth and 
Narvekar 2015).  
1.6.1.2 Silica 
These nanoparticles are commonly made of amino silicane especially for gene delivery due 
to its low toxicity (Kneuer, Sameti et al. 2000). They can also be produced from sand and 
glass (Ramamoorth and Narvekar 2015). Silica nanoparticles can be easily modified with 
aminosilanes at lower pH to produce a net positive charge, and are able to electrostatically 
interact with the DNA (Kneuer, Sameti et al. 2000). The interaction with serum protein is the 
major disadvantage of silica particles because it leads to a decrease in the delivery efficiency 
(Dizaj, Jafari et al. 2014). 
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1.6.1.3 Gold 
Gold nanoparticles are a promising area of research for gene therapy due to their low 
toxicity, ease of preparation, inert nature, and multiple surface characterizations (Ding, Jiang 
et al. 2014, Ramamoorth and Narvekar 2015). Gold nanoparticles work by interacting with 
the nucleic acid through electrostatic interaction due to the presence of cationic quaternary 
ammonium groups (McIntosh, Esposito et al. 2001), which in turn protect the DNA from 
enzymatic degradation. Gold nanoparticles have the ability to absorb near the infra-red light, 
which can penetrate deeply into the cells to deliver the DNA. The main problem of gold 
nanoparticles is its chemical stability that results from the accumulation of nanoparticles 
rather than being dissolved, which could lead to cell death (Ramamoorth and Narvekar 2015, 
Riley and Vermerris 2017).   
1.6.2 Organic synthetic/natural materials 
Transfection vectors are based on cationic lipid, cationic polymer, lipid nano emulsion (Nam, 
Park et al. 2009, Fraga, de Carvalho et al. 2015), solid lipid-based nanoparticles (Ezzati 
Nazhad Dolatabadi and Omidi 2016), and peptide-based (Riley and Vermerris 2017) 
materials are widely being investigated and all well described in the literature. In this section, 
given that this thesis emphasizes gelatin-based nanoparticles, we will focus only on cationic 
lipids and cationic polymers only.  
1.7 Cationic Lipids as Non-viral Systems for Gene Delivery  
Cationic lipids complexed with DNA (also called lipoplexes - Figure 1.7-1) are considered 
one of the most efficient non-viral vectors for DNA transfection. Cationic lipids consist of a 
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hydrophilic head group, typically linked to two hydrophobic hydrocarbon chains that which 
allow them to assemble into various aggregated structures, including vesicles and bilayers, 
among many others. The hydrophilic head group of cationic liposomes consists of positively 
charged functional groups (most commonly primary, secondary, tertiary amines, quaternary 
ammonium salts, guanidine, imidazole, pyridinium, phosphorus, and arsenic groups) that 
have the ability to complex with negatively charged naked DNA through electrostatic 
interaction resulting in complexes called lipoplexes. Cationic liposomes have been examined 
in safety studies through different routes of administration such as intratumoral, 
intrapulmonary, intracerebral and intravenous with little or no toxicity reported in any of 
these studies (Clark and Hersh 1999). Liposomes also have other advantages such as 
simplicity of preparation, low toxicity, low immunogenicity, ability to produce in large 
amounts, biocompatibility, and their versatility for use with any size or type of DNA/RNA 
(Hung, Huang et al. 1999, Pezzoli, Kajaste-Rudnitski et al. 2013, Fisher, Mattern-Schain et 
al. 2017).  
Dioleylpropyltrimethylammonium chloride (DOTMA) and dioleoyltrimethyl-
ammonium propane (DOTAP) (Stamatatos, Leventis et al. 1988, Mintzer and Simanek 2008, 
Yin, Kanasty et al. 2014) are the most commonly used cationic lipids used for gene delivery. 
In 1987, DOTMA was used by Felgner and colleagues as the first application of cationic 
liposomes to gene therapy (Felgner, Gadek et al. 1987). 
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Reproduced with permission from (Malam, Loizidou et al. 2009)  
The hydrophobic region traps drugs or DNA in the central core when the liposomes are 
prepared. The outer surface can be functionalized with ligands for active targeting or 
PEGylated.  
 
1.7.1 Helper lipids  
Most lipoplex formulations contain “helper” lipids, such as dioleoylphosphatidyl- 
ethanolamine (DOPE) or cholesterol (Chol), which provides extra stability to the 
lipoplexes (Kaur, Slavcev et al. 2009). DOPE has exhibited promising transfection 
efficiencies in both in vitro and in vivo gene delivery investigations (Farhood, Serbina 
et al. 1995, Hui, Langner et al. 1996). DOPE is generally thought to improve 
transfection efficiencies by assisting with the escape of the DNA from the endosome 
after cellular uptake (Mochizuki, Kanegae et al. 2013). Combination of cationic lipids 
and DNA in a micellar or liposomal form generally leads to a lamellar organization 
with DNA molecules sandwiched between lipid bilayers. Some systems, for example, 
those that contain the neutral lipid DOPE, result in the formation of an inverted 
Figure 1.7-1: Schematic illustration representing the structure of liposome 
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hexagonal structure containing DNA in the center of the inverted hexagonal bilayers 
(Mochizuki, Kanegae et al. 2013). According to Zhou and Huang (Wang and Huang 
1989), under physiological conditions, DOPE is a hexagonal phase-forming lipid 
(lipoplexes) thought to contribute to its ability to increase the transfection efficiency 
of DNA-liposome complexes by destabilizing the lamellar structure of the endosomal 
membrane lipids. Also, DOPE can also help the lipoplexes to escape the endosome 
through membrane charge density mechanism. In this mechanism, DOPE can trigger 
lamellar (LCα) to inverted hexagonal phase (HCII) transitions when the pH drops to 
acidic condition at late endosome. At the hexagonal phase (HCII), the curvature of 
DOPE has a negative charge, which results in an elastically frustrated state with the 
outer positive lipid monolayer of the cationic lipid. This state establishes a driving 
force for rapid fusion with the cell and endosomal membrane (Lin, Slack et al. 2003, 
Ewert, Ahmad et al. 2005).  
1.7.2 Stealth liposomes 
Stealth liposomes are poly-ethylene glycol (PEG)-coated liposomes, which have been 
recognized to be important for liposomal drug delivery (Immordino, Dosio et al. 2006). PEG 
is a linear polyether diol that possesses several useful properties, such as biocompatibility, 
solubility in aqueous and organic media (Davidson 1980), a lack of toxicity, very low 
immunogenicity (Dreborg and Akerblom 1989), and with good excretion kinetics (Yamaoka, 
Tabata et al. 1994). The molecular weight and structure of the PEG can be easily modulated 
for specific purposes, and it is easy and inexpensive to conjugate the polymer to a lipid. It has 
been demonstrated that grafting of PEG onto liposomes has many biological and 
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technological advantages. According to Maria et al., the most important properties of 
PEGylated vesicles are their strongly-reduced mononuclear phagocytic system (MPS) 
uptake, and their prolonged blood circulation; consequently, they improve distribution in 
perfused tissues (Immordino, Dosio et al. 2006). In addition, PEG chains on the liposome 
surface prevent aggregation both with other vesicles and with serum proteins, and thus 
improving the stability of formulations. Moreover, PEGylation can provide a scaffold on the 
surface of liposomes for conjugation of different ligands, and have the ability to enhance 
intracellular delivery, cell-type specific delivery, triggered release, imaging capabilities, 
tissue localization, and so on (Torchilin 2012). PEGylated liposomal doxorubicin (PLD) was 
the first, and is still the only, stealth liposome formulation to be approved in the USA and 
Europe for the treatment of Kaposi’s sarcoma (Krown, Northfelt et al. 2004), and recurrent 
ovarian cancer (Rose 2005).   
 Lipoplexes also have some drawbacks which include low transfection efficiency and lack 
of target specificity (Xu, Kumar et al. 1997). In addition, the formation of the lipoplex 
complex involves interaction among lipid molecules, in addition to that with DNA itself. A 
major driving force for the complex formation is the release of low-molecular weight 
counter-ions that makes a large entropic contribution to the free energy of binding (Matulis, 
Rouzina et al. 2002). The lipids’ hydrophobic segments are determinant in the macroscopic 
characteristics of the ensuing liposomes, particularly their size, shape, and stability in the 
dispersed state, as well as in their interactions with other lipids, cell membranes, and DNA. 
This, in turn, affects the transfection efficiency of the resulting lipoplexes. Furthermore, 
liposomal formulations often require an adjuvant, such as DOPE, for efficient delivery (Hui, 
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Langner et al. 1996). Liposomes also suffer from the lack of structural integrity, which leads 
to content leaking and instability during storage (Maurer, Fenske et al. 2001).  
Table 1.7-1: Chemical structures of most common cationic and helper lipids used for gene 
delivery 
Name of Lipid  Chemical Structure  
DOPE  
 
DOTAP 
 
DOTMA                    
 
Cholesterol-DC 
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1.7.3 Gemini surfactants  
Gemini surfactants have generated a great deal of research interest, and are considered a 
suitable replacement for cationic lipids (Ahmed, Kamel et al. 2016, Islam, Shortall et al. 
2017). The term “gemini surfactant” was first introduced by Menger in 1991 (Menger and 
Littau 1991) to mainly describe dimeric bis-surfactants having a rigid spacer linking two 
surfactant moieties. Gemini surfactants are molecules consisting of two head groups (polar or 
charged) and two aliphatic chains linked by a rigid or flexible spacer (Menger and Littau 
1991) (Figure 1.7-2). They are easily synthesized at a low cost, which is a significant 
advantage for industrial drug manufacturing. Gemini surfactants exhibit numerous 
advantageous properties including low critical micelle concentrations (CMC) and high 
surface activities. A low value of CMC is significant when considering surfactants as 
transfection vectors.        
 
 
 
 
 
 
 
 
 
A 
B 
Figure 1.7-2: General structure of gemini surfactant (A), structure of the m-s-m 
gemini surfactants (B). Adapted from (Wettig, Verrall et al. 2008) 
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The effect of variations in both the length of alkyl tails and the size of nature of spacer group 
of gemini surfactants has been demonstrated in many studies. Changes in the length of alkyl 
tail affect the properties of the surfactant solution in the same way as in traditional 
monomeric surfactants (Zana and Xia 2003). For example, an increase in the length of alkyl 
tail of gemini surfactant with a fixed spacer group increases the kraft temperature and 
decreases the natural logarithm of the CMC linearly (Zana and Xia 2003, Wettig, Verrall et 
al. 2008). Variations of spacer group of gemini surfactants are more complex because they 
result from steric, electrostatic, and hydrophobic interactions that serve to give rise to a rather 
rich array of aggregate structure in the solution (Zana 2002, Wettig, Verrall et al. 2008, Zhi, 
Zhang et al. 2013, Ahmed, Kamel et al. 2016) . 
 The cationic m-s-m gemini surfactant series is the most commonly studied family of 
gemini surfactants, where m and s refer to the alkyl tail length and the number of carbon 
atoms in the polymethylene spacer respectively. The first appearance of m-s-m type of 
gemini surfactant used for transfection, was in 2001 in a study by Rosenzwing and 
colleagues, who determined that surfactants having C6 spacer and oleyl (cis-9-octadecene) 
tails resulted in the highest overall transfection and, in particular, that the addition of the 
neutral helper lipid DOPE (1,2-dioleyl-sn-glycerin-ophosphatidlyethanolamine) diminished 
transfection efficiency (Rosenzweig, Rakhmanova et al. 2001). Helper lipids work as a 
stabilizing agent for the DNA-gemini surfactant complexes with C10, C12, and C14 tails 
(Fisicaro, Compari et al. 2005). Badea has determined that transfection efficiencies are best 
for spacer group of size s≤4 or s≥12. The short spacing (where s=2, 3 and 4, as well as their 
increased transfection efficiency can be explained in terms of optimizing interaction with 
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DNA phosphate groups (Badea 2006). The same group also reported that the transfection 
efficiencies with 16-3-16 increased when the alkyl tail length increased, either in the 
presence or absence of DOPE. Our group has been focusing on gemini surfactants as gene 
delivery systems for several years: thus, different modifications were applied to improve the 
transfection efficiency such as phytanyl substituted gemini surfactant (Wang, Kaur et al. 
2013), and pyrenyl gemin surfactant (Al Muslim, Ayyash et al. 2017). Also, we studied the 
effect of counterions on gemini surfactant 16-2-16 (Islam, Shortall et al. 2017), as well as the 
effect of the combination of Pluronic block copolymers with gemini surfactant 16-3-16 
(Madkhali 2014).  
1.8 Polymers as Non-viral Systems for Gene Delivery 
Cationic polymers/DNA complexes (also called polyplexes) possess excellent 
biodegradability, low cytotoxicity, triggered nucleic acid release, and higher transfection 
efficiency over many other lipoplexed systems (Wang, Su et al. 2012, Zhou, Liu et al. 2012, 
Li, Yuan et al. 2013). These polymers have the ability to condense, encapsulate, or complex 
DNA to be used for gene transfection (Wong, Pelet et al. 2007) (Figure 1.8-1). Also, cationic 
polymer formulations are easier to prepare as aqueous solutions than lipid formulations due 
to the enhanced solubility of the cationic polymer relative to lipids (due primarily to the long 
chain, hydrophobic alkyl tails present in the lipid structure). In addition, they are more stable 
during storage, and they are easy to manipulate through chemical modification to achieve 
high efficiency or cell targeting without the loss of activity (Tros de Ilarduya, Sun et al. 
2010). Consequently, cationic polymers appear to be the most widely investigated group of 
non-viral vectors, and they are promising to be one of the most successful delivery systems. 
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Figure 1.8-1: Packaging of DNA using polymer. The three main strategies employed to 
package DNA using polymers are via (1) electrostatic interaction, (2) encapsulation within or 
(3) adsorption onto biodegradable nano- or microspheres. Reproduced with permission from 
(Wong, Pelet et al. 2007) 
 
Several references in the literature have shown the transfection efficacy of these polymers 
both in vitro and in vivo (De Smedt, Demeester et al. 2000, Shi, Dan et al. 2010, Sun and 
Zhang 2010, Liang, Liu et al. 2012, Bose, Arai et al. 2015, Huang, Zhao et al. 2016, 
Vaidyanathan, Chen et al. 2016). The most common polymers used for gene delivery are 
discussed below.  
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1.8.1 Polyethyleneimine (PEI) 
Polyethyleneimine, which is being recognized as a gold standard gene carrier (Boussif, 
Lezoualc'h et al. 1995, Wang, Niu et al. 2015), has a positive charge and can interact through 
electrostatic interaction with the negative charge of DNA to form nanocomplexs. PEI, as a 
delivery system, is very efficient for transfection due to its large buffering capacity, which 
facilitates endosomal escape using the "proton sponge" mechanism (Varkouhi, Scholte et al. 
2011) and thus enhancing the gene delivery to the nucleus. Transfection efficiency of PEI 
basically depends on molecular weight. PEI with MW higher than 25 kDa demonstrated 
higher transfection efficiency, whereas PEI with MW lower than (800-2000 Da) revealed low 
transfection efficiency (Goula, Benoist et al. 1998, Fischer, Bieber et al. 1999, Godbey, Wu 
et al. 1999, Lee, Cho et al. 2008). The main drawback of PEI is its high toxicity (Lee, Cho et 
al. 2008).  
1.8.2 Poly-L-lysine (PLL) 
Poly-L-lysine (PLL) was one of the first cationic polymers used for gene delivery. PLL has a 
strong positive charge on the lysine amino acids. Although PLL has good biodegradability in 
the biological system, its use in vivo is very limited due to its poor circulatory half-life (~ 3 
min). PLL rapidly attaches to the plasma protein once it enters the circulatory system, which 
is rapidly removed from the circulation, and consequently results in low transfection 
efficiency (Nishikawa, Takemura et al. 1998, Dash, Read et al. 1999). The combination of 
DNA and PLL complexes achieves a size less than 100 nm in diameter. These complexes can 
be covalently attached to the target ligands of PLL, which can be used in different cell lines 
(Zauner, Ogris et al. 1998, Farrell, Pepin et al. 2007).  
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1.8.3 Chitosan 
Chitosan is a natural, biodegradable, biocompatible, and cationic polysaccharide used for 
gene delivery. Since chitosan is a polysaccharide, it is water soluble, and its degradation 
products are non-toxic, non-immunogenic, and non-carcinogenic (Alves and Mano 2008). 
Chitosans are linear polysaccharide containing β-(1-4)-linked D-glucosamine and N-acetyl-D-
glucosamine, primary amino groups, and primary and secondary free hydroxyl groups which 
make it easy to modify chemically (Köping‐Höggård, Mel'nikova et al. 2003, Alves and 
Mano 2008, Mourya and Inamdar 2008). The main problem of chitosan is its limitation in 
biomedicine because it only dissolves in a mildly acidic solution. However, due to its 
versatile property, several derivatives have been developed in terms of solubility such as 
amphiphilic chitosan. Amphiphilic chitosan achieved small particles size (~200 nm), and has 
been effectively used in gene delivery (Kean, Roth et al. 2005, Dong, Mao et al. 2006).  
1.8.4 Dextran 
Dextran is also a natural and biocompatible polysaccharide made of several glucose 
molecules. The straight chains of dextran consist of α-1,6-glycosidic linkage between glucose 
molecules, while the branches begin from α-1,3-glycosidic linkage (Purama, Goswami et al. 
2009). Dextran can be easily modified by conjugating primary amine groups such as 
spermine to produce cationic dextran (D-SPM) (Hosseinkhani, Hosseinkhani et al. 2011). D-
SPM is water soluble and possesses a positive charge of +42, which is responsible for the 
nonspecific binding of polyplexes or polymer to plasma protein (Hosseinkhani, Abedini et al. 
2015). D-SPM complexes can also be modified by adding PEG in order to increase the 
circulation time the in the circulatory system. Polyplexes of PEGylated D-SPM revealed an 
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increase in transgene expression, and are distributed in more organs including liver, lungs, 
spleen, and kidneys, compared to non-PEGylated polyplexes (Hosseinkhani, Azzam et al. 
2004). 
Table 1.8-1: Chemical structure of the common polymers used in gene therapy 
Generic Name Chemical Name Chemical Structure 
PEI     Polyethyleneimine      
NH2
NH
NH2
n
 
PLL Poly(L-lysine)                         
 
Chitosan  
 
  31 
Dextran  
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1.9 Gelatin Nanoparticles for Gene Therapy Applications  
1.9.1 Introduction to gelatin 
Gelatin is a natural polymer that is extracted from animal collagen through either partial acid 
or alkaline hydrolysis (Figure 1.9-1). There are two types of gelatin: cationic (gelatin type 
A), and anionic (gelatin type B) (Table 1.9-1) (Wang, Boerman et al. 2012, Elzoghby 2013). 
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Figure 1.9-1: Extraction of gelatin from collagen. The production of type A (cationic) 
gelatin is shown on the right of the figure; the production of type B (anionic) gelatin is shown 
on the left of the figure. Reproduced with permission from (Hosseinkhani, Abedini et al. 
2015) 
  
  33 
Table 1.9-1: Typical specification for commercial gelatin 
*Bloom number: as determined by the Bloom gelometer, it is an indication of the strength of a gel 
formed from a solution of known concentration. The Bloom unit is a measure of the force (weight) 
required to depress a given sample area of gel (a distance of 4 mm); the higher the Bloom number, the 
stronger the gel (GMIA 2013). 
 
Gelatin is distinguished from other synthetic polymers by having amino acid sequences such 
as Arg-Gly-Asp (RGD) in its structure. These amino acid sequences modulate cell adhesion; 
consequently, they play a significant role in gelatin’s final biological performance in 
comparison to other synthetic polymers that lack these cell-recognition sites (Wang, 
Boerman et al. 2012). Gelatin consists of eighteen non-uniformly distributed amino acids 
with both positive and negative charges (Samal, Dash et al. 2012). Since gelatin is derived 
from collagen and is found in large amounts in animals, gelatin does not produce harmful 
byproducts after enzymatic degradation (Elzoghby 2013). As a result, gelatin is considered as 
GRAS (generally regarded as safe) according to the United States Food and Drug 
Administration (FDA); and thus, it has been used in pharmaceutical, cosmetics, and food 
products for decades (Lemieux, Vinogradov et al. 2000, Kommareddy, Shenoy et al. 2005, 
Elzoghby, Samy et al. 2012). The FDA has also approved gelatin for extravascular 
Characteristics  Type A Type B 
Gel strength (bloom)* 50-300 50-250 
Isoelectric point (IEP) 7-9 4.8-5 
pH 3.8-5.5 5-7.5 
Extraction  from pig skin type 1 collagen from bovine collagen 
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administration, and it is widely used as a stabilizer in vaccines (Zwiorek 2006, Lee, Khan et 
al. 2011). 
Its biodegradability, compatibility, availability and low production cost have attracted 
many researchers to use gelatin experimentally. Due to its animal origin, gelatin has low 
antigenicity compared to collagen because gelatin is denatured from collagen during 
extraction processes, which causes a change in the molecular composition of gelatin’s many 
amino acids (Kommareddy, Shenoy et al. 2005, Elzoghby, Samy et al. 2012). Furthermore, 
gelatin has a flexible structure that can be easily modified by changing its functional groups 
with different cross linkers and targeting-ligands. This ability to be easily modified could be 
very beneficial in improving and developing potential gene and drug delivery systems, with 
minimal toxic effects on the host cells (Busch, Schwarz et al. 2003, Zhou and Regenstein 
2006, Wang, Boerman et al. 2012). Generally, gelatin is a promising gene and drug delivery 
system due to its multiple advantages and safety features, as noted above.  
1.9.2 Chemical structure of gelatin  
Gelatin is an amphiphilic polymer having both cationic and anionic charges along with 
hydrophobic groups present in the approximate ratio 1:1:1, which makes this polypeptide 
special (Elzoghby 2013). Gelatin has a triple helical structure (Gly-X-Pro), composed mainly 
of glycine and proline amino acids, with X representing the third amino acids. These amino 
acids mostly include alanine, lysine, arginine, methionine and valine (Flory and Weaver 
1960, Sahoo, Sahoo et al. 2015) (Table 1.9-1). Lysine and arginine represent 13% of gelatin, 
and both possess a positive charge; 12% of the polymer is negatively charged glutamic and 
aspartic acid groups. The hydrophobic group consists of leucine, isoleucine, methionine, and 
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valine representing 11% of gelatin’s structure. The remaining chain includes glycine, proline, 
and hydroxyproline (Elzoghby 2013).  
 
Figure 1.9-2: General chemical structure of gelatin 
 
Table 1.9-2: Amino acid composition of pigskin gelatin  
Reproduced with permission from (Farris, Song et al. 2009) 
Amino acids  Pig skin gelatin (mole %) Amino acids  Pig skin gelatin (mole %) 
alanine 11.05 leucine 2.35 
arginine 4.96 lysine 2.65 
asparagine 0.60 methionine 0.32 
Aspartic acid  4.42 Phenylalanine 1.38 
proline 13.10 serine 3.40 
glutamic acid  7.10 histidine 0.45 
glycine 32.20 threonine 1.80 
hydroxyproline 9.80 tyrosine  0.35 
hydroxyleucine  0.75 valine  1.90 
isoleucine 1.02   
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1.9.3 Gelatin nanoparticles for gene therapy  
1.9.3.1 Systemic gene delivery  
Several advantages make gelatin an effective vector for gene delivery. First, as an intrinsic 
protein structure, gelatin nanoparticles (GNPs) have the ability to conjugate to different 
moieties that stimulate receptor-mediated endocytosis due to the presence of amino and 
carboxylic functional groups. They can also encapsulate multiple plasmids, and the 
transfection efficiency can be improved by protecting the encapsulated plasmids from 
digestion using long-circulating PEGylated nanoparticles or nucleases (Kaul and Amiji 2005, 
Kommareddy, Shenoy et al. 2005). The first GNPs as non-viral vectors for gene delivery 
were developed by Kaul and Amiji in 2002 (Kaul and Amiji 2002), using gelatin type B. 
They studied the way the GNPs could encapsulate nucleic acid. The first study revealed that 
the negative charge of gelatin type B could physically encapsulate nucleic acid at neutral pH 
7.0; however, the nucleic acid could be condensed electrostatically when it interacted with 
the positive charge of lipids or polymers. When plasmid DNA exists in a hydrogel-type 
matrix, it is protected in the systemic circulation and upon cellular transport. Also, the 
released plasmid DNA forms a supercoiled structure at the nuclear membrane, which is very 
significant in obtaining an effective transfection because of its minimal size, which improves 
gene transfer and potential bioavailability (Darquet, Cameron et al. 1997, Magadala and 
Amiji 2008). Modifying the surface of gelatin with a quaternary amine such as cholamine 
enables the negative charge of the nucleic acid to be adsorbed on the surface of GNPs, thus 
increases ionic interactions (Zwiorek, Bourquin et al. 2008). The Amiji group has studied the 
effectiveness of non-condensing type B gelatin for systemic and oral gene therapy. GNPs 
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loaded with TMR-dextran as a model hydrophilic drug in BT-20 cells used to study cell 
trafficking showed that the particles were mainly taken up by endocytosis, and subsequently 
escaped the endosome through the proton sponge effect (Zhang, Ma et al. 2013); and were 
also found to be contained in the perinuclear area in the cytoplasm (Kaul and Amiji 2002, 
Kaul, Lee-Parsons et al. 2003). Another study indicated that most of the GNPs were 
internalized in NIH-3T3 fibroblast cells within the first six hours of incubation. After 12 
hours of incubation, green fluorescent protein expression was observed, which remained 
stable for approximately 96 hours with 43% transfection efficiency (Kaul and Amiji 2005). 
GNPs containing LacZ plasmid in the tibialis anterior muscle of 6-week old BALB/c mice 
showed powerful and sustained gene expression compared to naked DNA and Lipofectamine 
complexes in vivo (Leong, Mao et al. 1998). A successful encapsulation and an effective 
intracellular delivery of GNPs containing siRNA have also been demonstrated in the 
literature (Xu, Ganesh et al. 2012). For example, siRNA encapsulated in GNPs revealed high 
stability, even in an RNAse rich environment. HIF-1α siRNA loaded GNPs showed 
important downregulation in SKOV3 cells (Leong, Mao et al. 1998, Shah 2010, Xu, Ganesh 
et al. 2012).  
1.9.3.2 Oral gene delivery  
Gelatin nanoparticles have also been used to deliver nucleic acid through oral administration. 
A unique multi-compartmental oral delivery system was developed by Bhavser and Amiji 
(Bhavsar, Tiwari et al. 2006, Bhavsar and Amiji 2007, Bhavsar and Amiji 2008). This system 
is based on encapsulation of DNA-GNPs in poly (epsilon-caprolactone) (PCL) microsphere 
using a technique termed “double-emulsion-like”. This delivery system was called 
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‘’nanoparticles-in-microsphere oral system’’ or (NiMOS). The role of NiMOS is to protect 
the DNA during its travel to the stomach. When lipases-enzymes in the intestinal tract 
degrade the PCL matrix, DNA-GNPs are then internalized by enterocyte, or any other cell in 
the GI lumen to express the required protein (Bhavsar, Tiwari et al. 2006, Bhavsar and Amiji 
2007, Bhavsar and Amiji 2008, Kriegel, Attarwala et al. 2013).  
Significant EGFP and Beta-galactoside expression were observed in the small and 
large intestines after oral administration of NiMOS in fasted Sprague-Dawley rats (Bhavsar 
and Amiji 2008). In addition, interleukin-10 plasmid DNA and GNPs were encapsulated in 
PCL for the treatment of inflammatory bowel disease (IBD). The complex was then 
administered orally in an acute colitis model. IL-10, placed in the large intestine, was able to 
increase the level of mRNA and proteins, and reduce the levels of proinflammatory cytokines 
such as IFN-γ, IFN-α, IL-1α, IL-1β, and IL-12, in addition to certain chemokines (Bhavsar 
and Amiji 2008). These studies demonstrated that GNPs are potential and promising delivery 
vehicles for both systemic and oral gene delivery.   
1.9.4 PEGylated gelatin nanoparticles  
GNPs are mainly engulfed by the cells of the reticuloendothelial system (RES) upon 
systemic administration, which leads to weak transfection and gene expression. However, 
coating the GNPs with poly (ethylene glycol) (PEG) generates a dense hydrophilic shell of 
long chains that conserve the core of GNPs from non-specific hydrophobic interaction with 
serum protein; thus, it significantly reduces the effect of RES (Otsuka, Nagasaki et al. 2003). 
Another advantage of PEGylation is that it may increase the hydrodynamic size of the 
particles, which leads to a decrease in their clearance from the kidney, as the renal filtration 
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is dependent on the molecular mass and volume. These advantages result in an increase in 
circulation half-life of the particles in vivo (Crawford 2002, Kommareddy, Tiwari et al. 
2005). In addition, the existence of PEGylation on the surface of the GNPs helps in 
protecting the particles from digestion by proteolytic enzymes (Xu, Ganesh et al. 2012). 
Adding PEG to non-condensing type B GNPs has been shown to result in an excellent 
system to distribute effectively in solid tumor because of the hyperpermeability angiogenic 
blood vessels in tumors and the enhanced permeability and retention (EPR) effect (Kaul and 
Amiji 2004, Kaul and Amiji 2005). According to Amiji and Kaul, PEGylated GNPs 
favorably targeted tumor mass in Lewis lung carcinoma (LLC) bearing female mice, where 
about 4-5 % of the injected dose remained in the tumor for approximately twelve hours after 
administration (Kaul and Amiji 2004). Amiji and Kaul also stated that reporter pDNA 
encoding for β-galactosidase (pCMV-β) was effectively encapsulated in PEGylated GNPs 
and showed significant expression in LLC tumors with 61% transfection efficiency (Kaul and 
Amiji 2005). Kushibiki and colleagues (Kushibiki, Matsuoka et al. 2004) studied the long-
circulation property of PEGylated gelatin using 125I-labeled gelatin. They compared between 
unmodified GNPs and PEGylated 125I-labeled GNPs after I.V. administration through the tail 
vein in LLC-bearing mice. They found that PEGylated GNPs have longer circulating 
properties in the blood and remained in the tumor for up to 24 hours post-administration. In 
another study thiolated PEGylated GNPs exhibited prolonged circulation and enhanced 
tumor extravasation in vivo in an orthotopic human breast adenocarcinoma xenograft model 
(Kommareddy and Amiji 2007). Comparing with the non-PEGylated GNPs, the PEGylated 
nanoparticles showed longer circulation with plasma and tumor half-lives of 15.3 and 37.8 
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hours respectively. Generally, the advantages of the combination of PEG with GNPs are 
summarized as follows: increasing the circulation time in the plasma and tumor mass; 
stabilizing the therapeutic cargo during transportation; preventing RES elimination; and 
providing a potential for conjugation of targeting moieties.  
1.9.5 Thiolated gelatin nanoparticles  
The thiol group (SH) has been considered as a potential addition to GNPs due to its ability to 
respond to the environment changes either inside or outside the cells. The thiol group is 
similar to alcohol in chemical structure but differs in its chemical properties. Thiols are more 
nucleophilic, more acidic, and more readily oxidized (Senning 1997). Adding thiol groups to 
gelatin leads to the formation of disulfide bonds (S-S) in an oxidation reaction within the 
polymer, which can be beneficial in strengthening the tertiary and quaternary protein 
structure in the case of gelatin (Bacalocostantis, Mane et al. 2013). Also, disulfide bonds can 
stabilize the nanoparticles during systemic circulation, and release the encapsulated payload 
when they are broken inside the cell (Kommareddy and Amiji 2005). Groups of thiols are 
easily and rapidly crosslinked; therefore, they can be used for the synthesis of polymeric 
delivery vectors (Bacalocostantis, Mane et al. 2013). Conjugating thiols with PEG has been 
shown to improve stability and circulation time of the polyplexes in vivo (Bacalocostantis, 
Mane et al. 2013). Glutathione (GSH) is a dipeptide, used as an antioxidant to prevent 
damage caused by an oxygen species. GSH and peroxide exist in high concentration inside 
the cells more so than outside (100-fold higher), and their concentration is much higher in the 
cytoplasm of tumor cells. As a result, Kommareddy and Amiji (Kommareddy and Amiji 
2005) introduced a thiol (SH) group into gelatin using 2-iminothilane reagent and prepared 
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the nanoparticles by desolvation using ethanol under adjusted and controlled condition of pH 
and temperature. The plasmid DNA was then incorporated into the thiolated gelatin 
nanoparticles. The thiolated GNP encapsulated DNA showed high transfection efficiency in 
NIH-3T3 murine fibroblast cells in contrast with unmodified gelatin and lipofectin®-
complexed DNA (Kommareddy and Amiji 2005). Six hours after transfection, the expression 
of green fluorescent protein was observed. These results could be interpreted such that it was 
the disulfide bonds that increased the stability of the nanoparticles and indicated that 
thiolated GNPs have a rapid release of their contents into a highly reducing environment 
inside the cell where the high concentration of GSH (Kommareddy and Amiji 2005, 
Kommareddy and Amiji 2007). Furthermore, the same group evaluated three modifications 
of gelatin: PEG-GNPs, thiolated-GNPs, and PEG-modified thiolated GNPs in NIH-3T3 to 
deliver plasmid DNA. Among all three formulations tested, PEG-thiolated GNPs showed the 
highest GFP expression even more than the positive control lipofectin-complexed DNA 
(Kommareddy and Amiji 2007). Generally, both PEG-GNPs and PEG-modified thiolated 
GNPs demonstrated longer circulation in the blood and higher accumulation in the tumor 
cells in contrast with unmodified GNPs (Xu, Ganesh et al. 2012). A new tumor-targeted 
siRNA delivery system using polymerized siRNA (poly-siRNA) and thiol-modified gelatin 
nanoparticles was developed by Lee et al. (Lee, Yhee et al. 2013). The poly-siRNA was 
prepared by self-polymerization of thiol group and was encapsulated in the self-assembled 
thiolated-GNPs using chemical cross-linking. The results revealed that the siRNA was 
protected from enzymatic degradation, and the siRNA molecules were released effectively in 
reductive condition. Also, poly-siRNA-thiolated –GNPs demonstrated excellent 
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accumulation in the tumor cells, induced effective target gene silencing in tumors after 
intravenous injection, and showed high cell viability (closer to 100%) compared to 
lipofectamine and non-thiolated siRNA-GNPs (Lee, Yhee et al. 2013). Clearly, the disulfide 
bonds formed by (thiol) group could play a significant role in the stability of nanoparticles, 
thereby resulting in effective gene expression and high cell viability.  
1.9.6 EGFR-targeted gelatin nanoparticles  
One of the greatest challenges for gene delivery is targeting. A delivery vector is required to 
distinguish the host cells, evade nonspecific binding, and resist degradation in the systemic 
circulation. After reaching the target cells, the delivery vector should cross the cell 
membrane, facilitating the escape of the vector from the endosome, and release the nucleic 
acid from the complex, which can then enter the nucleus to express the required protein (Xu, 
Gattacceca et al. 2013). Although tumor targeting using PEG surface modified nanoparticles 
accomplishes some preferential accumulation in the tumor cells and allow for intracellular 
delivery, there are certain types of cancer that do not have adequate vasculature or the 
nanoparticles may not be able to penetrate deep into the tumor mass (Xu, Ganesh et al. 
2012). Mutation of epidermal growth factor receptor (EGFR) has been shown to be 
associated with poor prognosis in several types of cancers including ovarian cancer 
(Ciardiello and Tortora 2001). Between 33 and 75% of EGFR has reported to be 
overexpressed in ovarian cancer, and has been found in both the growth and progression of 
this disease (Sewell, Macleod et al. 2002). OVCAR-3 (cell line used in this project) showed a 
high level of EGFR protein expression (Noske, Schwabe et al. 2011); consequently, targeting 
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of EGFR using the OVCAR-3 cell line is possible and could improve the transfection 
efficiency.   
EGFR is a member of the ErbB/her family of ligand activated receptor tyrosine 
kinases (RTKs) that has been recognized as a molecular target. EGFR consists of an 
extracellular ligand-binding domain similar to any other receptor of tyrosine kinases that is 
involved in interactions between receptors within the membrane, and a cytoplasmic domain 
with tyrosine kinase activity (Schlessinger 2002). Consequently, conjugation gelatin with 
EGFR- targeted peptide has been shown to improve the transfection efficiency in several 
types of cancer cells. EGFR-targeted GNPs carrying plasmid DNA encoding for EGFp-N1 
obtained the highest transfection efficiency in Panc-1 pancreatic adenocarcinoma cells in 
compared to other controls, particularly 48 hours after transfection (Magadala and Amiji 
2008). As another example, transfection of EGFR-targeted GNPs with p53 induced a rapid 
apoptosis process in Panc-1 cells (Xu and Amiji 2012). Intravenous injection of EGFR-
targeted GNPs to a mice bearing Panc-1 pancreatic adenocarcinoma showed nearly double 
efficiency of targeting in comparison to PEG-GNPs and unmodified GNPs. In addition, it 
accumulated and was sustained longer in the tumor mass (Xu, Gattacceca et al. 2013). 
Another study conducted by Xu and Amiji used EGFR-targeted thiolated gelatin 
nanoparticles to deliver plasmid DNA into Panc-1 pancreatic adenocarcinoma cells (Xu and 
Amiji 2012). The EGFR improved the targeting, and the thiol group enhanced the stability of 
GNPs. The results showed that EGFR-targeted thiolated GNPs had nanoparticles that were 
small in size (150-200 nm) with high GFP expression, even higher than the positive control 
lipofectin-complexed DNA; they also obtained high cell viability (Xu and Amiji 2012). 
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Using targeting-ligands with GNPs facilitated the delivery system’s recognition of the host 
cell. As a result, the transfection was improved, and the cytotoxicity was reduced, which is 
the optimal goal for gene therapy delivery systems. 
1.9.7 Cationic gelatin and its importance for gene delivery 
As is the case for any polymeric system used as a gene delivery vector, it is necessary for 
gelatin to carry a positive charge (i.e. be cationic) in order to interact with the negatively 
charged DNA and cell membrane. According to the literature, positively charged particles are 
favorable phagocytosed by dendritic cells and macrophage more than the negative or neutral 
charged particles (Coester, Nayyar et al. 2006). Gelatin is a polyelectrolyte with low charge 
density; however, the charge density is appreciably changed according to the solution pH. As 
a result, cationization of gelatin is a significant factor in obtaining an effective gene delivery 
vector (Zwiorek, Kloeckner et al. 2005). Cationic gelatin is prepared mainly by introducing 
amine residues to the carboxyl groups of gelatin using polyethyleneimine (Mimi, Ho et al. 
2012), cholamine (Fuchs, Klier et al. 2012),  ethylenediamine (Xu, Capito et al. 2008, 
Ishikawa, Nakamura et al. 2012, Xu, Singh et al. 2014), or spermine (Zorzi, Párraga et al. 
2011).  
Cationized gelatin containing plasmid DNA expressing insulin-like growth factor 
(IGF)-1 has shown a five-fold elevation in the amount of IGF in adult articular chondrocyte 
compared to non-cationized gelatin. Also, chondrocytes treated with pIGF using cationized 
gelatin were able to maintain stable IGF-1 overexpression when later grown in collagen (type 
II)-glycosaminoglycan (CG) scaffold for up two weeks and exhibited enhanced biosynthesis 
(Xu, Capito et al. 2008).  Another example is polyethyleneimine (PEI), which has a high 
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positive charge, was conjugated onto the surface of GNPs to deliver pCMV-Luc and gene 
presented optimal transfection efficiency with high cell viability (Kuo, Huang et al. 2011). 
Basically, the existence of positive charge with GNPs will play a major role in improving the 
transfection efficiency and decreasing the cell toxicity, which is the optimal goal to obtain an 
effective delivery system for gene therapy.  
1.10 Pluronic Block Copolymers for Gene Therapy Applications 
1.10.1 Pluronic block copolymers 
Pluronic block copolymers, also called poloxamers, are nonionic polymers consisting of 
hydrophilic poly (ethylene oxide) (PEO) and hydrophobic poly (propylene oxide) (PPO) 
blocks arranged in triblock structure: EOx-POy-EOx (Kabanov, Lemieux et al. 2002) (Figure 
1.10-1).  
OH CH2CH2O CH2CHO CH2CH2O H
CH3
Polyethylene Oxide(PEO)
Polypropylene Oxide(PPO)
hydrophilic hydrophilic
hydrophobic
 
Figure 1.10-1: General chemical structure of Pluronic block copolymers 
This arrangement engenders an amphiphilic copolymer in which hydrophobic PO and 
hydrophilic EO segments can be modified to change the size, hydrophobicity, and 
hydrophilicity of the Pluronic (Kabanov, Lemieux et al. 2002). Copolymers with various PO 
  46 
and EO values are characterized by a distinct hydrophilic lipophilic balance (HLB) 
(Kabanov, Lemieux et al. 2002), which relates to the suitability of a particular polymer for a 
specific application. Sriadibhatla’s studies claim using that copolymers of intermediate 
hydrophobicity (HLB 9-16) with relatively large hydrophobic blocks (30-69 PO units) were 
the most effective in gene expression (Sriadibhatla, Yang et al. 2006).  
      Lack of solubility and stability in the biological fluid was the primary limiting factor of 
the first generation of polyplexes. The particle size of the polyplexes is very sensitive to the 
nature of salts that are present in the buffer and serum components (Ogris, Steinlein et al. 
1998, Nguyen, Lemieux et al. 2000).  As a result, Pluronic block copolymers overcame this 
barrier by forming micelles that reduce unwanted interactions between cells and/or proteins 
with a Pluronic-solubilized compound, and increases its circulation time due to the existence 
of PEO blocks (Kabanov, Lemieux et al. 2002, Kabanov, Zhu et al. 2005) 
     Due to their amphiphilic character, Pluronic copolymers display surfactant properties, 
which have the ability in aqueous solution to self-assemble into micelles above the critical 
micelle concentration (CMC) at fixed temperature, or above the critical micelle temperature 
(CMT) at a fixed concentration - a process called micellization (Kabanov, Lemieux et al. 
2002, Xiong, Binkhathlan et al. 2012). The number of block copolymer unimers forming one 
micelle is known as the aggregation number. The hydrophobic PO core of the micelle can 
serve as a “cargo hold” for incorporating various therapeutic and hydrophobic components 
(Kabanov, Zhu et al. 2005, Batrakova and Kabanov 2008). In addition, the existence of 
hydrophobic PO block enables the pluronic unimers to interact with the lipid membrane and 
translocate inside the cells (Kabanov, Zhu et al. 2005). On the other hand, the hydrophilic EO 
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shell keeps the micelle in a dispersed state, prevents undesirable interactions with other cells 
and proteins, and increases its circulation time (Kabanov, Lemieux et al. 2002, Kabanov, Zhu 
et al. 2005). Polymeric structures often tend to precipitate in water due to a localized 
hydrophobicity caused by the drug and the hydrophobic portion of the polymeric chain. 
However, with a core/shell structure, the polymer may remain in water-soluble if the number 
of monomers in the shell-forming block exceeds the core-forming block (Lavasanifar, 
Samuel et al. 2002).  
     Copolymers enhance gene expression using a mechanism that does not condense the 
DNA. It is possibly because copolymers act as biological adjuvants which enhance transgene 
expression by changing the response of the cells to the delivered DNA (Kabanov, 
Sriadibhatla et al. 2010), as discussed in detail in the next section.  
1.10.2 Pluronic block copolymer for gene therapy applications  
Several studies in the literature review have demonstrated that Pluronic block copolymers 
significantly increase expression of plasmid DNA in skeletal muscle, spleen, and lymph 
nodes as well as they stimulate plasmid DNA uptake and expression in antigen presenting 
cells in mice (Lemieux, Guerin et al. 2000, Alakhov, Lemieux et al. 2001, Yang, Zhu et al. 
2005, Sriadibhatla, Yang et al. 2006). Pitard and colleagues have discovered that a 
formulation containing single pluronic copolymers with plasmid DNA also enhanced the 
gene transfer in the muscle. In particular, Pluronic L64 improved the level of transfection 
efficiency more than naked DNA in the skeletal and cardiac muscle (Pitard, Pollard et al. 
2002). 
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     Copolymers also increase expression of genes delivered using polycation-DNA 
complexes, improve transfection with adenovirus and lentivirus vectors both in vivo and in 
vitro, and improve gene expression with different delivery routes and different vectors 
including naked DNA (Kabanov, Zhu et al. 2005). A recent study combined F127 with 
cationic copolymers including poly(dimethylaminoethyl methacrylate), poly(dimethylamino-
ethyl methacrylate-tert butyl acrylate), and poly(dimethylaminoethyl methacrylate-acrylic 
acid). Pluronic F127 was used as a means of reducing the cytotoxicity of the cationic 
copolymers and for self-assembly. The results demonstrated high gene expression and low 
cytotoxicity in 293T cells particularly with poly (dimethylaminoethyl methacrylate-acrylic 
acid) (Huang, Wang et al. 2013). In addition, Chen and colleagues (Chen, Zhang et al. 2014) 
successfully synthesized a series of F127-PEI-SS/pDNA complex formed by crosslinking 
disulfide –containing PEI (800 Da). The results demonstrated that in the presence of 
Pluronics, the complex showed high stability against DNase I or serum and higher 
transfection efficiency and viability than PEI-25 KDa, both in Bcap and Hela cell line. 
Among all tested Pluronics (P123, F127, L61, L35, and L64), which were added to the F127-
PEI-SS/pDNA complex, L35 with HLB of 19 showed the highest transfection efficiency and 
noticeable longer blood circulation time than other Pluronics and PEI-25 KDa. Moreover, 
Pluronics F87 and F108, in combination with cationic gemini surfactant 16-3-16, were able 
to deliver pDNA in OVCAR-3 cell line with a transfection efficiency (~ 15%) compared to 
lipofectamine 2000 (33 %) (Madkhali 2014).  
     Despite the above results, the mechanism of action of gene expression of Pluronics is not 
completely understood (Kabanov, Batrakova et al. 2002). However, Kabanove et al. 
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(Kabanov, Batrakova et al. 2002) have speculated some mechanism(s) of action for 
Pluronics. Also, when Pluronics interact with the cellular membrane, they facilitate cellular 
uptake of polyplexes (Astafieva, Maksimova et al. 1996) and naked DNA (Lemieux, Guerin 
et al. 2000). In addition, Pluronics enhanced DNA distribution through the muscle (Lemieux, 
Guerin et al. 2000), and they increased transport of DNA from the cytoplasm in the nucleus 
of the muscle cells (Pitard, Pollard et al. 2002). Generally, the mechanisms of action in which 
Pluronics enhance gene expression are different from those of cationic lipids or polycations 
(Flotte, Afione et al. 1993).  
 Given the above, Pluronic block copolymers are promising agents as nonviral vectors for 
gene therapy applications. Pluronic can modify the biological response during gene therapy 
which leading to enhancement of gene expression and therapeutic effect of the transgene. 
Also, Pluronics are able to form novel self-assembling gene delivery vectors that have 
superior efficacy to currently known systems. In addition, Pluronics block copolymers have 
shown some promise as formulation agents (Kabanov, Lemieux et al. 2002). 
1.11 Gelatin-Pluronic-based Nanoparticles as Non-viral Vectors for Gene Therapy 
In addition to its ability to complex DNA, gelatin is capable of forming nano-complexes with 
different polymers through various mechanisms. These mechanisms include ionic 
complexation, graft copolymerization, or self-assembly (i.e., micelle-like nanospheres) when 
combined with hydrophobic polymers (Elzoghby 2013). Gelatin-polyacrylic acid (GEL-PPA) 
nanoparticles were prepared using a polymerization mechanism without the addition of either 
organic solvents or additional surfactants (Wang, Zhang et al. 2009, Ding, Zhu et al. 2011). 
GEL-PPA nanoparticles were formed due to the electrostatic interaction between ionized 
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carboxyl groups of PPA and protonated amino groups of gelatin, and due to hydrogen 
bonding between the unionized carboxyl group of PPA and carbonyl groups of gelatin. 
Subsequently, cisplatin was loaded into this complex using a ligand exchange reaction of 
platinum (II) from the chloride to the carboxyl group of the nanoparticles. These 
nanoparticles (GEL-PPA-Cisplatin) exhibited significantly superior anticancer efficacy in 
hepatic H22 tumor-bearing mice as opposed to cisplatin alone (Ding, Zhu et al. 2011). In 
another study, different molecular weights of PEI (600, 1.8k, and 10kDA) were added to 
gelatin nanoparticles prepared using two-step desolvation and loaded with plasmid DNA 
(Kuo, Huang et al. 2011). Transfection efficacy and cell viability were investigated. The 
findings demonstrated that low molecular weight of PEI (1.8 kDa) showed high transfection 
efficiency with low cell toxicity. Gelatin-PEI nanoparticles showed a stable particle size of 
200 nm and obtained a positive charge during all ranges of pH, remaining stable in both 
acidic and basic condition (Kuo, Huang et al. 2011). These studies showed that the 
combination of gelatin and polymer as non-viral vectors nanoparticles is possible and 
effective.  
1.12 Scope of Thesis 
This thesis focuses on gelatin-based non-viral vectors for gene therapy. Gelatin nanoparticles 
were prepared and modified with a cationic agent to increase the positive charge in order to 
interact with the DNA and plasma membrane. Pluronic block copolymers were added to 
gelatin nanoparticles and characterized to study the effectiveness of this complex. This 
complex was then investigated using the Langmuir monolayer study and tested at cell culture 
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to evaluate its transfection efficiency and cell viability of delivering plasmid DNA. The 
thesis is comprised of six chapters: 
Chapter 1: 
Literature and Introduction to Gene Therapy: This chapter provides a brief introduction 
to gene therapy and the methods of delivering DNA using viral and non-viral vectors.  
Chapter 2: 
Hypothesis and Objectives: This chapter discusses the hypothesis of this work, as well as 
the objectives we used to investigate our hypothesis.  
Chapter 3: 
Characterization of Gelatin Nanoparticles and Cationic Gelatin Nanoparticles: This 
chapter describes the methods used throughout the thesis, including the preparation methods 
for gelatin and modified gelatin nanoparticles, and the characterizations used to test our 
particles at different conditions.  
Chapter 4: 
Understanding the Interaction of Gelatin/Pluronic/DNA System with Model membrane: 
Langmuir Monolayer Study: This chapter reports on the results of the Langmuir 
monolayer/BAM studies, and provides new understanding of the interaction of 
gelatin/Pluronic/DNA complexes with model membranes at the air/water interface. 
 
Chapter 5:  
Transfection Efficiency and Cell Viability of Gelatin/Pluronic/DNA System with COS-
7: This chapter reports the ability of gelatin/Pluronic/DNA complexes to transfect DNA in 
vitro using COS-7 cells.  
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Chapter 6:  
Conclusion and Future Studies: The chapter summaries this thesis, and a recommends 
future studies that might be conducted using gelatin/Pluronic/DNA systems to both optimize 
their transfection efficiency, and to provide further insight into the transfection 
mechanism(s). 
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 Hypothesis and Objectives 
2.1 Aim of the Thesis  
The aim of this thesis is to design an effective non-viral delivery system that is capable of 
delivering DNA in vitro. Gelatin was selected as a cationic agent, which was combined with 
Pluronic block copolymers in order to protect the DNA from degradation during its journey 
into the cell.  
2.2 Hypothesis 
Nanoparticles prepared from cationic gelatin and pluronic block copolymer can effectively 
complex DNA and interact electrostatically with the cell membrane, therefore improving the 
transfection efficiency of DNA.  
2.3 Objectives 
1. Preparation of gelatin nanoparticles: gelatin nanoparticles were prepared from type A 
gelatin using the two-step desolvation method.  
2. Preparation of cationic gelatin: cationic gelatin nanoparticles were prepared by 
introducing a cationic agent (cholamine) to the native gelatin nanoparticles.    
3. Preparation, optimization, and characterization of cationic gelatin-Pluronic-DNA 
transfection complexes: cationic gelatin and Pluronics were prepared, optimized, and 
characterized in the presence of plasmid DNA by studying the physiochemical 
properties as follows:  
a) Measuring of particles size using dynamic light scattering: for all systems 
including native gelatin, cationic gelatin, cationic gelatin-Pluronic-DNA complex.  
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b) Measuring of zeta potential of the particles using Laser Doppler Electrophoresis: 
for all systems including native gelatin, cationic gelatin, cationic gelatin-Pluronic-
DNA complex, as well as the effect of pH on both native and cationic gelatin.  
c) Imaging of nanoparticles using scanning electron microscopy (SEM), and 
transmission electron microscopy (TEM) were conducted for both native and 
cationic gelatin.  
4. Characterization the interaction (s) of cationic gelatin-Pluronic-DNA on the model 
membrane using Langmuir monolayer study at the air-water interface: the cationic 
gelatin-Pluronic-DNA system was investigated at air-water interface in combination 
with model biological membranes DPPC-CHOL and POPC-CHOL.   
5. In vitro transfection efficiency of cationic gelatin-Pluronic nanoparticles containing 
plasmid DNA: EGFP plasmid DNA was tested in cell line COS-7 to evaluate the 
transfection efficiency of cationic gelatin, and the cationic gelatin/Pluronic systems.  
6. Cell viability studies of transfected cells to assess the toxicity levels of this complex: 
the cell toxicity of the transfection system was also tested in COS-7, correspondingly 
with the transfection experiment, by adding the propidium iodide (PI).  
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 Characterization of Gelatin Nanoparticles and Cationic Gelatin 
Nanoparticles  
3.1 Introduction 
Nanoparticles for drug and gene delivery applications should not produce toxic by-products 
when biodegradability occurs inside the biological system. As a result, a potential and safe 
matrix molecule should be achieved for these nanoparticles. Several methods described in the 
literature in the last few decades used synthetic or natural polymers to prepare biodegradable 
nanoparticles for gene delivery. Examples of natural polymers include proteins such as 
albumin, gelatin, and collagen, polysaccharides such as chitosan and cyclodextrin, among 
many others; while synthetic polymers include cationic dendrimers, polyesters, 
polymethacrylates and polyethyleneimine (Nezhadi, Choong et al. 2009) (recall Chapter 1). 
Among these polymers, nanoparticles of proteinaceous origin such as albumin, collagen, and 
gelatin generate more interest. Gelatin, as mentioned in Chapter 1, is a natural polymer 
extracted from collagen. Gelatin has several accessible moieties that enable multiple 
modification opportunities for coupling such as targeting-ligands, crosslinkers, and shielding 
substances. Preparing gelatin as nanoparticles for gene delivery is important for several 
reasons. Firstly, nanoparticles are taken easily and efficiently by cells more so than large 
particles (Panyam and Labhasetwar 2003). Secondly, nanoparticles have the ability to escape 
rapidly from the endosome and therefore, are protected from degradation (Labhasetwar 
2005). In addition, nanoparticles have been demonstrated to improve the transfection 
efficiency of plasmid DNA into the nucleus (Prabha, Arya et al. 2016). Several methods have 
been employed to prepare gelatin nanoparticles since the 1970s. Two major methods are:   
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1. Preparing gelatin nanoparticles using desolvation of the protein by adding non-
solvent, salting-out, or focus on isoelectric point (IEP) by adjusting pH level. 
Examples of this kind of preparations include two-step desolvation, one-step-
desolvation, and nanoprecipitation.  
2. Preparing gelatin nanoparticles using a biphasic system. This method depends on 
emulsifying an aqueous solution of gelatin within an oily phase such as 
microemulsion and solvent evaporation techniques.    
Most of the preparation methods using emulsion are not appropriate for gene delivery due to 
some specific disadvantages. Firstly, the yield obtained from these methods is low comparing 
to other methods. Secondly, the broad size distribution of nanoparticles may result in 
aggregation of biological systems. Thirdly, the purification of nanoparticles using these 
methods are very complicated but are critically important in order to remove some organic 
phase(s) as well as to maintain the emulsification state of the nanoparticles. The last 
drawback of these methods includes the energetic methods that are necessary to generate 
nanoparticles, such as high-speed or high-pressure homogenization, or the use of ultrasound 
to disperse particles in order to obtain appropriate particle sizes (Zwiorek 2006). 
In this project, the two-step desolvation method was selected to prepare gelatin nanoparticles. 
Small particles size (~ 150 nm) with a low polydispersity index (0.06) can be achieved using 
this method. Also, a higher yield can be obtained compared to emulsification techniques. In 
addition, the high stability of nanoparticles (up to 3 months) was obtained using this method 
(Coester, Kreuter et al. 2000).  Finally, the method itself is simple and straightforward 
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(Coester, Kreuter et al. 2000). One-step desolvation and nanoprecipitation methods were also 
attempted in this project, and then compared to the two-step desolvation.  
In this chapter, we also describe the characterization of modified gelatin. Gelatin 
nanoparticles were modified by adding a cationic agent (cholamine) in order to increase the 
positive charge of gelatin. As mentioned earlier in Chapter 1, a positive charge is necessary 
to interact with the negative charge of DNA and cell membrane.   
3.2 Materials  
Gelatin type A (Protein content 81% Bloom ~300), (2-aminoethyl) trimethylammonium 
chloride hydrochloride (cholaminchloride hydrochloride), glutaraldehyde grade I 25%, 1-
ethyl-(3dimethylaminopropyl) carbodiimide (EDC), Sucrose (HPLC) 99.5%, and HCL were 
purchased from Sigma-Aldrich (Oakville, Ontario, Canada).  E.Z.N.A. Plasmid Maxi-Prep 
Kit was purchased from OMEGA Bio-Tek, (Georgia, USA). Acetone (99%) and Ethanol 
(99%) were purchased from Chem store, University of Waterloo.    
3.3 Methods 
3.3.1 Preparation of gelatin nanoparticles  
3.3.1.1 Two-step desolvation  
Gelatin nanoparticles were prepared using a two-step desolvation method previously 
described by Coester et al (Coester, Kreuter et al. 2000). In brief, 300 mg of gelatin type A 
was dissolved in 10 mL of distilled water under constant heating (45-50 ºC). 10 mL of 
acetone was added as a desolvating agent to precipitate the high molecular weight (HMW) 
fraction of gelatin. After the supernatant was discarded, the HMW gelatin was re-dissolved in 
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10 mL of distilled water and stirred at 600 rpm under constant heating. Subsequently, the pH 
was adjusted to 2.5 using HCL. After that, 25 mL of acetone was added dropwise to form 
nanoparticles. 48 µL glutaraldehyde (GA) 25% (v/v) was added as a cross-linking agent and 
stirred at 600 rpm at room temperature overnight. The next day, the nanoparticles were 
purified using dialysis membrane before freeze drying. Various concentrations of gelatin 
were optimized to determine the best nanoparticles in terms of the size and the homogeneity.  
3.3.1.2 One-step desolvation 
One-step desolvation was prepared as a modification to the standard two-step desolvation 
method (Ahlers, Coester et al. 2007). In this approach, the first step described above, which 
precipitates the high molecular weight, was omitted, while the remaining steps were carried 
exactly out as in the two-step method. This method was shown to be a robust in the 
preparation of gelatin nanoparticles (Geh, Hubert et al. 2016).   
3.3.1.3 Nanoprecipitation 
50 mg of gelatin type A was dissolved in 10 mL of distilled water under constant heating 
(40-45 ºC). This was then added drop-wise to 100 mL of ethanol containing 1600 mg 
Pluronic F127, used as an emulsifying agent to give 1:32 ratio of gelatin to Pluronic. 
Subsequently, 8 µL glutaraldehyde (GA) 25% (v/v) was added as a cross-linking agent and 
stirred at 600 rpm at room temperature overnight. The next day, the nanoparticles were 
purified using dialysis membrane before freeze drying.   
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3.3.2 Preparation of cationic gelatin 
After preparing GNPs using the two-step desolvation method (section 3.3.1), the 
nanoparticles were cationized by introducing amino residues (cholamine) to the carboxyl 
group of gelatin nanoparticles, as follows: The gelatin nanoparticles were dissolved in highly 
purified water, and then the pH was then adjusted between pH 4.5 and pH 5. 50 mg of 
cholamine was added and incubated for five minutes. Next, the same amount of EDC (50 
mg) was added to the solution and the reaction was left for 1 hour in the dark. Cationic 
gelatin nanoparticles were then purified using centrifugation or dialysis for two days before 
lyophilization. 
 
Figure 3.3-1: Schematic illustration of the preparation of cationic gelatin nanoparticles using 
one-step desolvation method. 
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3.3.3 Particle size measurement 
The particle size was measured using the Dynamic Light Scattering method (DLS) at 25 °C. 
This technique relies on the effect of time-dependent light scattering of the random motion of 
suspended particles (Brownian motion) that depends on particle size. The particles in a liquid 
move randomly, and their speed of movement was used to determine the size of the particle 
(Malvern 2013). The distribution of particle size in water was obtained from the light 
scattered by particles illuminated at a scattering angle of θ = 173°. Particle size 
measurements of gelatin nanoparticles, as well as Pluronic-based transfection mixtures 
(Chapter 5) were done using a disposable Solvent Resistant Micro Cuvette (ZEN0040) in a 
Malvern Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) which is a part of 
the School of Pharmacy’s core facility, while particle size distributions were calculated using 
the Malvern DTS software. The size measurements were carried out in triplicate, with the 
average size is reported as ± the standard deviation. The Malvern Zetasizer reports both an 
average size for the particle population (z-average) as well as sizes corresponding to peak 
intensity for the case of multiple particle populations. In all cases, the z-average size was 
used throughout this thesis. The polydispersity index (PDI) was measured along with the 
particle size measurements with an average PDI expressed as ± standard deviation. PDI 
measures the broadness of the size distribution, which was calculated from the cumulants 
analysis. PDI less than 0.3 is desired in pharmaceutical nanoparticles according to Malvern 
standard for Zetasizer instrument.  
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3.3.4 Zeta potential measurement 
Zeta potential (ζ) is the electrostatic potential that exists at the boundary between two layers 
of ions, namely, the compact and the diffuse layers, which surround a particle in solution. 
This is an important property for understanding colloidal and interfacial behaviors. Zeta 
potential was measured using a combination of the measurement techniques, namely, 
Electrophoresis and Laser Doppler Velocimetry (sometimes called Laser Doppler 
Electrophoresis - LDE). This method measures the speed at which a particle moves in a 
liquid when an electrical field is applied (i.e., its velocity). If all particles of the suspension 
mixture have a large positive or negative charge, they will repel each other, and there will be 
no tendency to fluctuate. On the other hand, low zeta potential values of the particles mean 
there is no force to prevent the particles from coming together, therefore resulting in 
fluctuation. Practically, particles with zeta potential more positive than +30 mV or more 
negative than -30 mV are considered to be stable (Wissing, Kayser et al. 2004).  
Similar to particle size measurements, zeta potential measurements of the gelatin 
nanoparticles as well as Pluronic-based transfection mixtures (Chapter 5) were done using a 
disposable capillary cell (DTS1070) and the Malvern Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, UK); zeta potential distributions were calculated using the 
Malvern DTS software. Similar to particle size, zeta potentials were automatically measured 
three times per sample, and are reported as the mean ± standard deviation. Also, the zeta 
potential of both native and cationic gelatin was measured at different pH values from acidic 
to basic. A pH meter was used to adjust the pH values, and the Zetasizer was used to measure 
the charge.  
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3.3.5 Scanning electron microscopy (SEM)  
Scanning electron microscopy (SEM) was used to visualize the gelatin nanoparticles and 
cationic gelatin to investigate their size and morphology. SEM images were taken using a 
Zeiss MERLIN FESEM 1530 microscope (part of the WATLAB facility at the University of 
Waterloo) equipped with a field-emission source and an acceleration voltage up to 25 kV, as 
well as Energy Dispersive X-ray Spectroscopy or (EDS) detector for surface elemental 
analysis. For sample preparation, gelatin nanoparticle suspensions were diluted ten times 
with their dispersion medium, after which a drop of the diluted nanoparticle suspension was 
directly deposited on a polished aluminum sample holder. Samples were dried under vacuum. 
Samples were then coated in gold using EMITECH K450X sputter coater prior to 
microscopical analysis. 
3.3.6 Transmission electron microscopy (TEM)  
Transmission electron microscopy was used to visualize the cationic gelatin in order to 
investigate the details of crystal structure and the morphology of the modified nanoparticles. 
TEM images were taken on Philips CM10 located in the Department of Biology, University 
of Waterloo. For the sample preparation, the gelatin nanoparticle suspensions were diluted 
twenty times with their dispersion medium, after which a drop was directly deposited on a 
400-mesh copper grid, and allowed to dry inside a desiccator for 24 hours prior to 
measurement.  
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3.3.7 Fourier transform infrared spectroscopy (FT-IR)  
Fourier Transform Infrared Spectroscopy (FT-IR) spectra were recorded on a Bruker 
TENSOR 27 FTIR spectrometer (Bruker, Germany). The attenuated total reflection (ATR) 
technique was used in this experiment. Samples of 3–5 mg of both native and cationic gelatin 
were ground and pressed into a Pike Miracle single-bounce attenuated total reflectance cell 
equipped with a Zn-Se single crystal. The scanning range was 500 - 4000 wavenumber (cm-1) 
with a scan speed of 10 kHz. 
3.3.8 Extraction and purification of plasmid DNA (pTGIFN-GFP) 
The plasmid encoding for interferon (IFN) protein and enhanced green fluorescent protein 
(pEGFP) was amplified in K-12 strains of Escherichia coli (a gram negative, anaerobic, rod-
shaped bacterium) (provided from Dr. Roderick Slavcev`s lab at the School of Pharmacy, 
University of Waterloo) in the generation of the recombinant cell constructs, extracted using 
centrifugation protocol of the E.Z.N.A.® Endo-Free Plasmid DNA Maxi Kit (OMEGA Bio-
Tek, Georgia, USA).  Before the extraction process of plasmids, a single colony of bacterial 
strain JM109 [pTGIFN] of Escherichia coli was grown overnight (18 – 20 hours) in 5 mL of 
growth media Luria-Bertani (LB) broth + Kanamycin (kan) antibiotic in a temperature-
controlled bench-top shaker (New Brunswick Scientific Excella™ E24, Fisher Scientific, 
US) at 250 rpm and 37 °C with circulating air supply. A new batch of cells were grown 
overnight from that last day culture at 1:100 dilution in 500 mL of growth media (within a 2 
L Erlenmeyer flask), at the same temperature and rpm. After the overnight treatment, the 
final culture was removed from the shaker when the A600 was ≈ 1.5, at which point 
indicated the exponential bacterial growth of the mid logarithmic phase. The extraction was 
  64 
then completed, followed by the E.Z.N.A.® Endo-Free Plasmid DNA Maxi Kit protocols. 
Two batches of 1.5 mL aliquot of the extracted plasmid in Milli Q water were prepared. The 
purity, yield, and integrity of the plasmid were measured and analyzed using UV 
spectrophotometry (NanoDrop 2000, Fisher Scientific, USA), and by gel electrophoresis 
(AGE) (Alpha-Imager HP, Alpha Innotech, Cell Biosciences, USA). The size of the pEGFP 
was 4.7 kb. The extracted plasmid stock was then immediately stored in a freezer at -20 Cº, 
as recommended in the protocol for further use.  
3.4 Results and Discussion 
3.4.1 Preparation of nanoparticles 
In order to understand our eventual observations of transfection utilizing the gelatin 
nanoparticles prepared in this work, it is important to understand how the parameters 
described in section 3.3.1 for the preparation of gelatin nanoparticles that impact the resulting 
properties of the nanoparticles. Here, we will discuss the effects of choosing the desolvation 
(or nanoprecipitation) method, and the choice of desolvation agent, temperature, pH, and the 
choice of crosslinking agent.  
3.4.1.1 Desolvation (or nanoprecipitation) method 
3.4.1.1.1 Two-step desolvation method  
As mentioned in the introduction, preparing gelatin nanoparticles using two-step desolvation 
can achieve homogeneous and stable nanoparticles. The values of the resulting nanoparticles 
(with respect to particle size and homogeneity) were tested using DLS. Based on the 
Zetasizer standard, size distribution of nanoparticles achieves a PDI below 0.1 are considered 
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typical, and DLS gives a monomodal distribution within this range. Four concentrations of 
gelatin (mg/mL) in water were prepared, and each concentration was measured before and  
after adding glutaraldehyde (GA) in order to obtain the best size and PDI (Figure 3.4-1). The 
average mean size and PDI for each concentration are reported, which were calculated using  
Zetasizer software.   
        
From the examination of Figure 3.4-1, it is clear that a nanoparticle concentration of 30 
mg/mL gave rise to the “best” nanoparticles in terms of a having both a small average 
particle size (115±0.5 nm) and low PDI (0.06±0.02) after crosslinking. The results results are 
also consistent with a recently published paper using the same type and bloom of gelatin 
Figure 3.4-1: Size (bars) and PDI (dots) of gelatin nanoparticles and reported as mean. A) 
before adding GA; and B) after adding GA. Samples were measured in triplicate and the 
average reported - errors are equal to standard deviation. PDI represents polydispersity index. 
GA represents glutaraldehyde.  
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(type A, 300) (Geh, Hubert et al. 2016). A concentration of 30 mg/mL was used to prepare 
gelatin nanoparticles for all subsequent experiments in this thesis. 
3.4.1.1.2 One-step desolvation method 
In order to obtain an adequate particle size and PDI, the one-step desolvation method was 
also applied. One-step desolvation was prepared as described in section (3.3.1) and in Figure 
3.3-1 using the same weight 30 mg/mL, and following the same standard conditions used for 
the two-step desolvation method. The one-step desolvation method gave particles with an 
average size of 104±0.08 nm, with a PDI of 0.08±0.05. These results were acceptable 
compared to the two-step method, although aggregation was very high, particularly after 
purification. Farrugia & Groves suggested that an increase of HMW and a reduction of low 
molecular weight (LMW) is significant in order to produce homogeneous and stable 
nanoparticles (Farrugia and Groves 1999), as achieved above using the two-step desolvation 
method. Also, Coester et al. (Coester, Kreuter et al. 2000) stated that the reduction of LMW 
is necessary to prevent aggregation during crosslinking, as well as to prevent secondary 
aggregation and fluctuation during storage. Zwiorek tried different batches of gelatin and 
found that gelatin batches containing less than 20% (w/w) of < 65 kDa molecular weight 
peptide resulted in the successful preparation of homogeneous and stable nanoparticles using 
the one-step desolvation method. In contrast, the gelatin batches containing molecular 
weights > 104 kDa failed to achieve homogenous and stable nanoparticles by one-step 
desolvation. Based on this data, Zwiorek then concluded that it is not important to have 
HMW in order to prepare homogenous and stable nanoparticles (as stated previously by 
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Farrugia & Groves), but it is crucial to have a strong reduction of LMW components (< 65 
kDa) for the stability and homogeneity of nanoparticles (Zwiorek 2006, Zillies 2007).  
3.4.1.1.3 Nanoprecipitation method  
For the preparation of GNP using the nanoprecipitation method, ethanol was used as a non-
solvent agent, and Pluronic F127 was used as a surfactant. Gelatin nanoparticles tend to 
aggregate during the preparation processes, and as a result, the formulation was optimized to 
obtain stable and homogenous nanoparticles. A range of different concentrations of gelatin 
and Pluronic F127 were used, giving rise to final conditions of: 
1. The amount of gelatin should be 1:32 to the amount of surfactant 
2. The amount of water should be 1:10 to the amount of ethanol.  
An average size of ~ 300 nm and a PDI of 0.05±0.03 were obtained, and the solution was 
cloudy with no visible agglomeration.  
All nanoparticles were analyzed using SEM for both two-step and nanoprecipitation 
methods in order to visualize and investigate the morphology of these nanoparticles (Figure 
3.4.2). SEM revealed the particles to be smooth, spheres, and were smaller than DLS. This 
reduction in size was due to dehydration of the nanoparticles (required for SEM 
measurements under vacuum conditions). The same observations were also noted in the 
literature for different polymer-based nanoparticles (Finsy, De Jaeger et al. 1992, Bootz, 
Vogel et al. 2004).     
By examining the three methods of preparing gelatin nanoparticles, we concluded that the 
two-step desolvation method is the best choice for this project for several reasons.  
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First, two-step desolvation has a smaller size than nanoprecipitation. Also, since our project 
focuses on using Pluronic block copolymers with gelatin, it is not beneficial to use the 
nanoprecipitation method, since different Pluronics will be compared in our experiments. As 
a result, the study of the Pluronics effect will not be accurate. In addition, due to the 
aggregation that might result from using one-step desolvation and the pH range, which has a 
narrow range, the two-step method was selected.  
3.4.1.2 Desolvating agent 
Gelatin nanoparticles are prepared using desolvating agents such as acetone or ethanol. 
Gelatin can dissolve in water due to the formation of hydrogen bonds between the water 
molecules and the hydrophilic amino acids of the gelatin. Adding desolvating agents into 
gelatin solutions leads to a reduction in water molecules surrounding the gelatin chains; 
therefore, it results in breakage of the hydrogen bonds and a decrease in hydration. When the 
hydration becomes very low, the loosely packed gelatin chains precipitate and form 
Figure 3.4-2: Scanning-electron-microscopy (SEM) images of the gelatin nanoparticles A) 
Tow-step desolvation, B) Nanoprecipitation. The particle size was determined about 60-100 
nm. 
 
A B 
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nanoparticles (Arroyo-Maya, Rodiles-López et al. 2012). Both acetone and ethanol have been 
shown to be effective in the preparation of gelatin nanoparticles (Von Storp, Engel et al. 
2012); however, Azarmi et al. found that gelatin nanoparticles prepared using acetone as a 
desolvating agent are smaller and have lower PDI compared to those prepared using ethanol 
(Azarmi, Huang et al. 2006). In the nanoprecipitation method, ethanol as a non-solvent agent 
was found to creat smaller particles than acetone; however, the difference was not 
statistically significant (Khan 2014).  
3.4.1.3 Temperature  
The temperature of the first and second desolvation in the two-step desolvation method 
should be between 45 °C and 50 °C. It is well-known from the literature, that gelatin can be 
easily affected by the temperature due to the occurrence of denaturation or renaturation 
processes (Farrugia and Groves 1999). Preparing gelatin nanoparticles at room temperature is 
impossible because gelatin is renatured and forms a viscous gel at this temperature (Sahoo, 
Sahoo et al. 2015). Temperatures above 56 °C results in reversible denaturation of the higher 
molecular fractions due to the disruption of hydrogen bonds, which lead to particles 
clumping (Sahoo, Sahoo et al. 2015). Temperatures between 35 °C and 40 °C are considered 
the sol-gel transition temperature (Peyrelasse, Lamarque et al. 1996). This means that the 
range between 40 °C and 55 °C is the ideal temperature to prepare gelatin nanoparticles. In 
this project, different ranges of temperatures were tested, and we determined that temperature 
between 45 °C and 50 °C is ideal.  
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3.4.1.4 Effect of pH on gelatin nanoparticles 
Since gelatin is an amphoteric polymer, it has both positive and negative charge. The size of 
gelatin nanoparticles is affected by the pH of the medium, which ultimately determines the 
net charge and charge density of gelatin molecules (Sahoo, Sahoo et al. 2015). Type A 
gelatin has an IEP in the range of 6.9 to 9.0. Within this pH range, nanoparticle formation is 
not stable and formed agglomeration due to the electrostatic attraction of the positive charge 
of NH3
+. At pH ranges between pH 2.3 and pH 3.8, it was possible to produce homogenous 
and stable nanoparticles with PDI less than 0.1 because of the increase in the ionic strength 
of the electrostatic repulsion of NH3
+ (Zwiorek, Kloeckner et al. 2005, Sahoo, Sahoo et al. 
2015). Above pH 4.0, the nanoparticles tend to agglomerate and precipitate because they 
become closer to IEP of gelatin type A (Azarmi, Huang et al. 2006). In our project, we 
determined that pH at 2.5 was the optimal value to prepare stable and homogenous 
nanoparticles.  
3.4.1.5 Cross-linking agent 
The addition of crosslinking to gelatin nanoparticles is important to provide stability, to form 
a spherical shape, and to enhance circulation times in vivo (compared to uncrossed-linked 
particles (Kommareddy, Shenoy et al. 2005, Elzoghby, Samy et al. 2012)). Gelatin 
nanoparticles tend to aggregate and become unstable when they are prepared without 
crosslinking (Sahoo, Sahoo et al. 2015). There are several crosslinking agents that were used 
in the preparation of gelatin nanoparticles, such as glutaraldehyde (Leo, Vandelli et al. 1997, 
Ofokansi, Winter et al. 2010), genipine (Song, Zhang et al. 2009), and glyceraldehyde 
(Vandelli, Rivasi et al. 2001). Glutaraldehyde (GA) is used as a non-toxic and effective 
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cross-linker in the preparation of gelatin nanoparticles as it does not induce aggregation and 
has been shown to maintain particles stable in solution for more than ten months at 
temperature between 2 °C and 10 °C (Leo, Vandelli et al. 1997, Azarmi, Huang et al. 2006). 
Lower amounts of GA are not sufficient to cross-link all particles; however higher amounts 
are not suitable as this could give rise to a significant size reduction due to the crosslinking of 
the free amino groups on the surface of gelatin nanoparticles (Azarmi, Huang et al. 2006).  
3.4.2 Stability of nanoparticles after freeze-drying 
Most nanoparticles tend to aggregate after freeze-drying and become difficult to redisperse 
due to the lyophilization process, which changes the properties and robustness of the 
nanoparticles (Fonte, Soares et al. 2014). In order to prevent the aggregation of gelatin 
nanoparticles, nanoparticles are required to remain spatially separated in the dried cake 
(Allison, dC Molina et al. 2000). During storage, moisture also plays a major role in the 
stability of gelatin nanoparticles. As a result, different excipients (cryoprotectants) were used 
to keep nanoparticles stable for an extended period of time. Examples of freeze-drying 
excipients used include trehalose, sucrose, and mannitol. Mannitol and mannitol-sucrose 
formulations have previously been confirmed to have the greatest stability for gelatin 
nanoparticles, with the nanoparticles staying stable for up to ten weeks (Zillies, Zwiorek et 
al. 2008). In our experiments, sucrose was chosen to be added to the gelatin nanoparticles as 
a cryoprotectant (Shilpi, Kushwah et al. 2017). Sucrose was dissolved in 2 mL of highly 
purified water (HPW) and added directly to gelatin nanoparticles before freeze-drying. Four 
ratios of sucrose to gelatin were used before freeze-drying (Table 3.4-1). It is apparent from 
the table that a sucrose concentration of 2.5% resulted in freeze-dried particles having the 
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smallest size of 116 nm, which is similar to the original size of the gelatin nanoparticles. 
Nanoparticles remained stable in our lab for approximately three months. This stability was 
confirmed by dissolving the gelatin in water and measuring the size and PDI after three 
months. The particles showed stability with no noticeable aggregation as they demonstrated a 
single peak in DLS data with no significant change in diameter.   
Table 3.4-1: Optimization of the amount of sucrose added to gelatin nanoparticles before 
freeze-drying. Samples were measured in triplicate, errors are equal to standard deviation. 
PDI represents polydispersity index. 
Size before 
sucrose (nm) 
PDI Concentration 
(w/w%) 
Size after 
sucrose (nm) 
PDI 
  1% 127±0.5 0.17±0.01 
115±0.5 0.06±0.02 2.5% 116±0.3 0.13±0.02 
  3.5% 119±0.1 0.13±0.008 
  5% 129±2 0.13±0.01 
 
3.4.3 Cationic gelatin  
As mentioned previously in the introduction, a positive charge is important for gene delivery 
in order to interact with the negative charge of DNA and the cell membrane. Gelatin 
nanoparticles are cationized by introducing a quaternary amino group onto the surface of the 
nanoparticles, as previously described in section (3.3.2). Although there are several amino 
agents that were used to cationoize gelatin, cholamine chloride was chosen in this project 
based on the previous study conducted by Zwiorek et al., (Zwiorek, Kloeckner et al. 2005). 
They tried different amino agents and discovered that cholamine was the best choice based 
on the particle size, PDI, and zeta potential. During cationization, cholamine can interact 
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with possible functional groups as shown in Figure 3.4-3. The first interaction is with 
residual aldehyde group derived from mono-functionally bound cross linking glutaraldehyde. 
The second interaction occurs between the amino groups of cholamine and the activated 
carboxyl groups of nanoparticles. Unlike other cationic agents, cholamine results in pH-
independent positive charges through the quaternary ammonium groups, which remain 
positive at all pH conditions as will be shown in pH data later in this chapter.  
3.4.4 Size and zeta potential of cationic gelatin  
The size of gelatin nanoparticles remains relatively homogenous and stable after 
modification. It is clear from Table 3.4-2 that the size and PDI of the gelatin nanoparticles 
increased after cationization from 115 nm to 173 nm, and from 0.06 to 0.2, respectively, and 
that the zeta potential increased from 11 mV to 32 mV. This increase in size may be the 
result of interparticulate covalent cross-linking (induced by the presence of EDC) between an 
activated carboxylic acid group on one particle, and a primary amino group on an adjacent 
particle. It could also result from a simply increase in the molecular weight of gelatin due to 
the addition of the cholamine groups. 
While the PDI increase is indicative of a decrease in the homogeneity of the cationic gelatin 
nanoparticles (i.e., a broader distribution of particle sizes), a PDI of 0.2 is still very consistent 
with examples from other non-viral vector systems (both liposomal or polymeric in nature).  
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Table 3.4-2: Particle size and zeta potential of native and cationized gelatin. Samples were 
measured in triplicate, errors are equal to standard deviation. PDI represents polydispersity 
index. 
Gelatin Type A Particle Size (nm) PDI ζ-Potential (mV) 
Native gelatin 115±0.3       0.06±0.02 11±0.4  
Cationic gelatin using 
cholamine as a cationic 
agent 
173±0.5  0.2±0.008 32±0.2 
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Figure 3.4-3: Schematic illustration of surface cationization of gelatin nanoparticles using 
cholamine. Reproduced from (Zwiorek 2006) 
 
EDC 
Cholamine 
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As for native gelatin nanoparticles, the cationic gelatin particles were also visualized using  
SEM. Figure 3.4-4 reveals that the cationic gelatin nanoparticles is very similar in size and 
morphology to those obtained with native gelatin. They are spherical in shape and they are 
attached to each other. The crystalline structure and the size were also investigated and 
analyzed using TEM through GMS3 software. Similar to what is observed from SEM, the 
cationic gelatin nanoparticles are approximately 95 nm in diameter and are crystalline with a 
plane separation of 30 Å (Figure 3.4-4). The decrease in size in TEM images is attributed to 
the method of preparation. In TEM, the sample is diluted more than in SEM. Also, the grid in 
TEM is much thinner than the SEM grid due the requirement to view the particles in high 
resolution. In addition, the drop of particles diffuses through the holes placed in the 
perforated grid. Then, the small particles are able to cross the streamline of the grid and stay 
on the carbon film. These results are in a bias to small particles (Baalousha, Ju‐Nam et al. 
2012, Tuoriniemi, Johnsson et al. 2014). Therefore, the results of TEM are determined to be 
unreliable because of the relic of sample preparation (Tuoriniemi, Johnsson et al. 2014). 
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As we mentioned previously, the addition of cholamine induced a pH-independent positive 
charge using the quaternary amino groups, which remained positive at all pH conditions. 
This is obvious from the Figure 3.4-5; where we tested both native and cationic gelatin at 
different pH conditions. It is clear from the figure that native gelatin has IEP ~ 9, while the 
cationic gelatin remained positively charged over the measured pH range. This means that 
the pH of the physiological environment should not affect the delivery system. 
Figure 3.4-4: SEM (top) and TEM (bottom) images of cationic gelatin nanoparticles 
A) at magnification 19000X, B) at magnification 92000X 
~ 95 nm 
A B 
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3.4.5 FT-IR 
In order to confirm the modification of gelatin, FT-IR was carried out for both native and 
cationic gelatin. The infrared spectrum of both native and cationic gelatin is shown in detail 
in Figure 3.4-6, with important peak positions listed in Table 3.4-3. Both native and cationic 
gelatin exhibit an amide I peak (C=O stretch) at 1655 cm-1 and 1654 cm-1, respectively, but 
the intensity is stronger in cationic gelatin. An amide A peak (N-H stretching vibrations) at 
3313 cm-1 was observed for both types of native and cationic gelatin which, combined with 
the amide I peak, is characteristic for gelatin. Cationic gelatin also has an amide II peak (N-H 
Figure 3.4-5: Zeta potential values at different pH conditions for both native and cationic 
gelatin. Samples were measured in triplicate. 
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bend and C-H stretch) at 1545 cm-1, and an amide III peak (C-N stretch plus N-H in phase 
bending) at 1247 cm-1 due to the presence of cholamine. The FTIR spectrum of cationic 
gelatin also shows an additional peak at 2991 cm-1, which might be associated with the C–H 
stretching from the cholamine groups (Jalaja, Naskar et al. 2015). Finally, a small peak at 1450 
cm-1 was also observed for the cationic gelatin, which might be attributed to aldimine 
absorption between the residual groups of glutaraldehyde and the amino groups of cholamine 
(Akin and Hasirci 1995). Glutaraldehyde has an aldehyde group (-CHO) that reacts with the 
free amino group to establish an aldimine linkage (CH = N) (Bigi, Cojazzi et al. 2001).  
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Figure 3.4-6: ATR-FTIR spectra of native and cationic gelatin 
 
Table 3.4-3: IR absorption frequencies of amides groups 
Bond Functional group Wavenumber (cm-1) 
N-H- (Stretching) Amides A 3100 - 3500 
C=O (Stretching) Amides I 1640-1690 
N-H- (Bending) Amides II 1550-1640 
C-N stretch plus N-H in 
phase bending 
Amides III 1247 
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3.4.6 Optimization of cationic gelatin and DNA  
Since our project focuses on gene delivery, plasmid DNA is used with cationic gelatin to 
form polyplexes between the negative charge of DNA and the positive charge of cationic 
gelatin. Cationic gelatin was dissolved in water and simply mixed with the DNA using w/w 
ratios listed in Table 3.4-4. It is clear from Table 3.4-4 below that particle size decreases 
upon increasing the amount of cationic gelatin. This decrease in size due to the increase of 
positive charge provided by cationic gelatin, which interacts electrostatically with the 
negative charge of DNA. As increasing amounts of gelatin is added, the DNA is more 
completely neutralized, resulting in a greater degree of compaction and smaller particle size. 
As expected, the zeta potential increases with an increase in the amount of cationic gelatin, 
and switches from negative to positive between w/w ratios of 10:1 and 15:1 CG:DNA). A 
ratio of 20:1 CG:DNA yielded particles that had the smallest diameter (163 nm with a 
polydispersity of 0.09) while still having a strong positive zeta potential (+21 mV). Particles 
containing less gelatin carried less positive charge, while particles containing more gelatin, 
increased in size. As such, a ratio of 20:1 CG:DNA was selected as the optimal formulation 
for the nanoparticles. While ideally a zeta potential more positive than 30 mV or more 
negative than -30 mV is desired, as they are considered stable (Wissing, Kayser et al. 2004), 
in the case of our system, it appears that cationic gelatin does not have a large enough total 
positive charge to continue to increase the zeta potential while avoiding aggregation. 
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Table 3.4-4: Particle size and zeta potential of different ratios of plasmid DNA and cationic 
gelatin (W/W ratios). Samples were measured in triplicate, errors are equal to standard 
deviation. PDI represents polydispersity index.  
Ratio (CG: DNA) Size (nm) Zeta (mV) PDI 
DNA alone  469±15 -50±2 0.5±0.03 
2.5: 1 193±5 -25±0.5 0.05±0.05 
5: 1 186±2 -18±0.2 0.2±0.02 
10: 1 182±2 -12±0.3 0.07±0.02 
15: 1 172±1 16±0.4 0.1±0.03 
20: 1 163±0.4 21±2 0.09±0.02 
50: 1 170±0.8 23±0.5 0.2±0.01 
3.5 Summary 
Gelatin nanoparticles were successfully prepared using a two-step desolvation method. In 
comparison to nanoprecipitation and one-step desolvation methods, the two-step desolvation 
provided the most homogeneous and stable nanoparticles. Parameters of pH equal to 2.5, 
acetone as the desolvating agent, temperature between 45 °C and 50 °C, and glutaraldehyde 
as the crosslinking agent were followed in order to obtain stable and homogenous 
nanoparticles. The removal of high molecular weight (HMW) fractions in the two-step 
desolvation method is considered to be an essential step in obtaining homogeneous and stable 
nanoparticles. Gelatin nanoparticles were then modified with cholamine as a cationic agent in 
order to increase the positive charge of nanoparticles, which is essential to interact with the 
negatively charged DNA and the cellular membrane. Nanoparticles became less 
homogeneous after they were modified with cationic agent (cholamine). The size increased 
from 116 nm to 173 nm, and the zeta potential also increased from 11 mV to 32 mV. 
Cationization of the nanoparticles was confirmed by conducting the FT-IR. Cationic gelation 
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nanoparticles showed a good tolerance and remained positive in all pH values, which is 
essential when they enter the biological system. Cationic gelatin was then mixed with DNA 
and it was determined that a ratio 20:1 CG:DNA gave particles having the smallest size (163 
nm) while still maintaining a moderately high, positive zeta potential of 21 mV.  
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: Understanding the Interaction of Gelatin/Pluronic/DNA System with 
Model Membranes: A Langmuir Monolayer Study 
The main goal of this chapter is to describe the interaction of our complete gene delivery 
system (gelatin -Pluronic-DNA) with model membranes comprised of DPPC-CHOL and 
POPC-CHOL. Four Pluronics were used (L44, F87, P103, and F108), covering a range of 
molecular weights and hydrophobic-lipophilic balances. The interactions of the nanoparticles 
with the model membranes were characterized using Langmuir monolayers, and measured 
using Langmuir isotherms; monolayers were also imaged using Brewster’s Angle 
Microscopy (BAM) as a means of visualizing any lipid domain changes that may have 
occurred.  Understanding these interactions can provide important insight into the interaction 
of these types of nanoparticles with cellular membranes and might provide information that 
could be used in the optimization of transfection formulations and help in improving 
transfection efficiency in vitro. 
4.1 Introduction to Langmuir Monolayer Studies  
The Langmuir-Blodgett (LB) monolayer technique, along with Brewster’s Angle Microscopy 
(BAM), provides an understanding of both the interactions between polymers and DNA, as 
well as how they interact with the biological membrane at the air/water interface. A 
Langmuir monolayer can be used as a model interface to allow for the study of film 
chemistry and film structure with changes in film compression, changes in sub-phase 
composition, and other changes such as pH and temperature (Ulman 2013). This technique 
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explains the homogeneity of the monolayer and formation of domains, phase transitions and 
adsorption of  
 
 
 
 
 
 
 
 
 
 
materials from the aqueous phase. The LB trough is coupled with Brewster angle microscopy 
(BAM) to view the domains of the floating monolayers (Figure 4.1-1).                                                                                                                                    
In a typical LB monolayer, compressing the barriers provides an isotherm of surface pressure 
as a function of mean molecular area (𝜋 –A) of the compounds spread on the surface of the 
sub-phase (Figure 4.1-2). Surface pressure is the difference between the surface tension of 
pure sub-phase (γo) and the monolayer covered phase (γ). At 20˚C pure water possesses a 
surface pressure of approximately -72 mN/m. A schematic of a Langmuir isotherm is shown 
in Figure 4.1-2 where the surface pressure of the two-dimensional monolayer increases as the 
Figure 4.1-1: A schematic of the Langmuir trough used to determine Langmuir isotherms; a) 
frame, b) barriers, c) the trough, d) surface pressure sensor, e) Dipping mechanism (LB option), 
and f) Interface unit. Reproduced from (http://www.ksvnima.com) 
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molecules in the monolayer are forced closer together (i.e. smaller molecular areas) and the 
monolayer shows different phase transitions. The phases which may be observed in 
Langmuir monolayers include: gaseous (G); liquid expanded state (LE); a coexistence region 
of LE and liquid condensed (LC) states; liquid condensed (LC) state; and a solid/like (S) 
state. In the G-phase, surfactant molecules remain far apart; as a result, no interaction is 
observed, and the surface pressure remains at or near Zero. Increasing the surface pressure 
(by compressing the barriers) decreases the area per unit molecule, forcing the molecules to 
begin interacting with one another; this initial interaction is termed the liquid expanded (LE) 
phase. In this phase, molecular interactions similar to those that would be expected if the 
material comprising the monolayer were in a true liquid state; although in this case, the 
interactions would be weaker than those seen in the pure liquid. Additional compression of 
the monolayer results in a steeper rise in surface pressure at slightly smaller areas, which 
results in the liquid condensed (LC) phase, where the molecules in the monolayer are now 
are closely packed (as compared to the LE phase); however, there is still anticipated to be 
some level of molecular motion. Finally, the monolayer reaches the solid (S) phase, as does 
the compressibility of the molecules, and therefore further compression of the monolayer 
causes monolayer collapse. In this region, surface pressure is observed to increase linearly 
with decreasing molecular area, and the minimum cross-sectional area (A0) for the molecules 
in the monolayer can be obtained by extrapolating from this region. In practical experimental 
conditions, monolayers may not show all these phases due to the narrow ranges of 
temperature and surface pressure that may be available.   
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Figure 4.1-2: Theoretical π -A isotherm obtained by compressing an insoluble lipid 
monolayer formed at an air-water interface. Reproduced from (Eeman and Deleu 2010) 
 
4.2 Cell Membranes 
The typical cell membrane is a bilayer membrane consisting of phospholipid molecules with 
embedded sterols and proteins (Figure 4.2.1). The lipids that make up the membrane can be 
divided into: glycerol-based lipids (phospholipids), ceramide-based sphingolipids, and 
cholesterol. According to the nature of their hydrophilic head groups, phospholipids are also 
divided into phosphatidylcholine (PC), phosphatidylethanolamine (PE), and 
phosphatidylserine (PS), among many others (Peetla, Stine et al. 2009). PC, also called 
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lecithin, is the major component of the cell membrane and pulmonary surfactant. It is more 
commonly used in the exoplasmic and the outer leaflet of the cell membrane (Wirtz 2006). It 
also plays a role in membrane mediated cell signaling and phosphatidylcholine transfer 
protein (PCTP) activation of other enzymes (Kanno, Wu et al. 2007). PE, also called 
cephalin, is the second most abundant phospholipid after PC, and is present in all eukaryotic 
and prokaryotic cells. The major role of PE is to assist in membrane fusion and in 
disassembly of the contractile ring during cytokinesis in cell division (Emoto, Kobayashi et 
al. 1996). PS is also found in all living cells, but in less amounts than in PC and PE. PS plays 
an important role in cell cycling signaling, particularly in relation to the early stage of 
apoptosis (Vance and Tasseva 2013).  
 
Figure 4.2-1: Structure of the human cell membrane.  Reproduced from 
(http://ruleof6ix.fieldofscience.com/2013/01/hiv-finds-cellular-door-knob-siglec1.html) 
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To provide a simplistic model for a cellular membrane, mixtures of the above lipids can be 
used to prepare Langmuir monolayers. It is recognized that this is a highly simplified model 
and completely negates the effects of membrane proteins; however, interactions that serve to 
disrupt lipid packing can be identified in this approach. 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), dioleoyl phosphatidylcholine (DOPC) and 1-palmitoyl-2-oleoyl-sn-
glycero-3- phosphocholine (POPC), in combination with cholesterol, are the most common 
mixtures used for model membrane studies (see Figure 4.2-2 for structures) (Escribá, 
González‐Ros et al. 2008). It is well known that a healthy membrane has a larger amount of 
cholesterol and saturated phospholipids, while tumor cell membranes contain higher amounts 
of unsaturated lipids such as POPC (Klock and Pieprzyk 1979). As a result, a cancer cell 
membrane is more fluid than a normal membrane (Inbar, Goldman et al. 1977). In this 
project, a mixture of 80% POPC and 20% cholesterol was used as a model membrane to 
mimic the cancer cell membrane (Wnętrzak, Łątka et al. 2013). Based upon literature data, it 
has been shown that endosome membranes (early or late) contain cholesterol in the range of 
25% to 30% (Guha, Rajani et al. 2007). As such, a mixture of 75% DPPC and 25% 
cholesterol was used as a model membrane to mimic the endosomal membrane.  
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Figure 4.2-2: Chemical Structures of A) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), B) 1-palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine (POPC), C) Cholesterol 
 
4.3 Materials 
Cationic gelatin was prepared as described in Chapter 3. Chloroform and double-stranded 
salmon sperm DNA (used without further purification) were purchased from Sigma-Aldrich 
(Oakville, Ontario, Canada). Pluronic block copolymers L44, F87, P103, and F108 were a 
gift from BASF Corporation (Florham Park, NJ) (Table 4.3-1). 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine (POPC), and 
cholesterol were purchased from Avanti Polar Lipids (Alabaster, USA).     
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Table 4.3-1: Physiochemical Characteristics of Pluronics Block Copolymers (Kabanov, Zhu 
et al. 2005) 
aThe average molecular weight provided by the manufacturer (BASF Co., Parsippany, NJ).                                            
bThe average numbers of EO and PO units were calculated using the average molecular weights.                                   
cHLB values of the copolymers the cloud points were determined by the manufacturer.                                                                
dCMC values were determined previously using Pyrene probe                                                                                                                                                                                                                                                                                                                                                                          
 
4.4 Methods 
4.4.1 Monolayer formation and surface pressure measurements  
CG was dissolved in Millipore-Q water to prepare a stock solution at a concentration of 1 
mg/mL. Salmon DNA was also dissolved in Millipore-Q water to prepare a stock solution of 
1 mg/6 mL. DPPC-CHOL was prepared at a ratio of 75%-25% (1.875 mM- 0.625 mM) while 
POPC-CHOL was prepared at a ratio of 80%-20% (2 mM-0.5 mM); both solutions were 
prepared so that the total lipid concentration was 2.5 mM. All Pluronics were dissolved in 
chloroform at a concentration equal to 1× their critical micelle concentration (CMC). 
Monolayers were prepared on a large (14.5 cm by 53 cm) Langmuir-Blodgett trough (KSV 
Instruments, Helsinki, Finland), using Milli-Q water as the subphase, as follows:   
Copolymer MWa Average no. of 
EO units 
(Npo)b 
Average no. of 
PO units 
(Npo)b 
HLBc CMC, Md 
L44 2200 20.00 22.67 16 3.6×10-3 
F87 7700 122.50 39.83 24 9.1×10-5 
P103 4950 33.75 59.74 9 6.1×10-6 
F108 14600 265.45 50.34 27 2.2×10-5 
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1. The trough was filled with Milli-Q water, to which DNA was added to obtain 0.2 
µg/mL as the final concentration (where required). 
2. 160 µL of cationic gelatin stock solution was then added into the subphase. A w/w 
ratio of 1:40 of DNA to CG was used in this study.  
3. A volume of 20 µL of Pluronic was next added to subphase (where required). A glass 
rod was used to mix CG with DNA or CG/DNA mixture with Pluronics prior to 
adding the monolayer as a final step.  
4. A volume of 20 µL of DPPC-CHOL or POPC-CHOL stock solution was placed onto 
the surface of the subphase using a micro-syringe (GASTIGHT®, Hamilton-Bonaduz, 
Schweiz, Switzerland). 
5. For experiments involving DNA, the monolayer was allowed to equilibrate for 30 
minutes. For experiments that did not involve DNA, the sub-phase was given 15 
minutes to equilibrate before adding monolayer. The monolayer was then allowed to 
equilibrate for another 30 minutes on the DNA and the subphase before the isotherms 
were collected. 
Surface pressure was monitored using the Wilhelmy plate method and the monolayers were 
compressed using barriers at a rate of 15 mm/min to obtain the surface pressure vs. molecular 
area. Isotherms and BAM images of the following samples with or without DNA were 
collected: CG and L44, CG and F87, CG and P103, CG and F108 with DPPC-CHOL and 
POPC-CHOL monolayers.   
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4.4.2 Imaging the monolayer                                                                                                                                                                                                                                                                        
Briefly, the Brewster angle microscope (BAM) (KSV Instruments, Helsinki, Finland) uses 
polarized light that shines incident to the surface of the water at the Brewster angle 
(approximately 53º). When a monolayer is applied onto the sub-phase, this changes the local 
refractive index (RI); as a result, a small amount of laser (He-Ne laser, with a power of 50 
mW, wave length of 658 nm) is reflected on the surface, and the monolayer image is then 
observed using a CCD camera, and analyzed using KSV NIMA Image software (Version 
1.1.2, KSV-NIMA, Finland).   
4.4.3 Analysis of the  - A isotherms 
A variety of parameters can be obtained from the isotherm. For example, limiting area or 
minimum cross-sectional area (A∞) is determined by regression of the linear region of the 
isotherm corresponding to the stiffest phase of the monolayer, prior to collapse. From the 
linear equation we can calculate the limiting area at which the surface pressure (i.e. y in the 
regression) is equal to zero. The monolayer is more closely packed when the value of 
limiting area is small (Chen, Zhang et al. 2008). Also, the collapse pressure (πC) can be 
determined from the isotherm, which corresponds to the maximum surface pressure on the y-
axis and before the collapse. The monolayer is stable when the surface pressure at collapse is 
high (Barnes and Gentle 2011). The molecular area at collapse (Ac), corresponds to the 
molecular area for the lipids in the monolayer, just at the point of collapse.  Both πC and AC 
are read directly from the isotherm.   
  94 
4.4.4  Compressibility modulus 
Interfacial elasticity describes the changes in surface tension regarding the area of the surface 
associated with a liquid film, which is actually related to the compressibility of the 
monolayer (Vollhardt and Fainerman 2006). As a result, based on the following equation:  
Cs
-1 = −A(∂π/∂A)T, 
the compressibility modulus (Cs
-1) was determined, where, A is the molecular area at a 
given surface pressure, π. The molecular area at collapse (Ac) and collapse pressure 
(πc) were directly determined from the compression isotherms. Davis and Rideal 
(Rideal and Davies 1963) stated that the phases of the monolayer are determined by 
the compressibility modulus, as follows:  
• Gaseous phase(G) Cs-1 < 12.5 mN/m 
• Liquid-expanded phase (LE) Cs-1 = 12.5–50 mN/m,  
• Liquid-expanded liquid condensed (LE-LC) Cs-1 = 50–100 mN/m,  
• Liquid-condensed (LC) Cs-1 = 100–250 mN/m, 
• Solid (S) for Cs-1 > 250 mN/m.  
The monolayer is less elastic when the Cs
-1 is high and vice versa. Since the surface 
pressure of the real biological membrane ranges between 30 mN/m and 35 mN/m 
(Seoane, Minones et al. 2000), we will focus on this surface pressure in this study. 
Strong or weak interactions were interpreted through the change that occurs to the 
parameters of model membranes, particularly limiting area and compressibility 
modulus, after the model membranes interact with the delivery system. A large change 
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in these parameters indicates strong interaction, while a slight change indicates weak 
interaction.       
4.5 Results and Discussion 
Since our monolayers were prepared using 75% DPPC or 80% POPC in addition to 
cholesterol, it is important to study the individual components of DPPC, POPC, and 
cholesterol to gain a better understanding of the behaviour of monolayers containing only 
these single components. Our group previously reported the analysis of isotherms for 
monolayers of pure DPPC, POPC, and cholesterol (Ahmed 2015). The results demonstrated 
that cholesterol formed a condensed monolayer in which the molecules were vertically 
arranged, or they slightly shifted towards the surface. These findings were in agreement with 
the results found in the literature (Seoane, Minones et al. 2000). DPPC shows a 
characteristics transition from LE to LC phase starting at surface pressure (5-7 mN/m) 
(Barnes and Gentle 2011), and the isotherm continues at LC until collapse while POPC 
shows a liquid-expanded phase with no noticeable transition until collapse.  
4.5.1 DPPC-CHOL and POPC-CHOL 
The isotherms for the DPPC-CHOL and POPC-CHOL systems are shown in Figure 4.5-1; 
parameters derived from the isotherms are listed in Table 4.5-1. Our results show that the 
DPPC-CHOL monolayer is more rigid than the POPC-CHOL monolayer. From the isotherm, 
the minimal cross sectional areas (A∞) were determined to be 41 Å
2 and 63 Å2 for both 
DPPC-CHOL and POPC-CHOL respectively, which indicates that DPPC-CHOL is more 
closely packed than POPC-CHOL (Chen, Zhang et al. 2008).  
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Figure 4.5-1: Isotherms (A and B) and compressibility modulus plots (C and D) for DPPC-
CHOL (A, C) and POPC-CHOL (B, D) in the presence and absence of DNA. 
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Table 4.5-1: Monolayer properties derived from isotherm and compressibility modulus plots, 
for untreated DOPC-CHOL or POPC-CHOL monolayers, and for monolayers treated with 
DNA. 
 
Molecular area at collapse (Ac), collapse pressure (πc), limiting (or minimum cross-sectional) 
area (A∞), compressibility modulus (Cs-1), determined from the value of Cs
-1 at surface 
pressure 30 and 35 mN/m, LE = liquid expanded, LC = liquid condensed. a Phase of the 
monolayer based upon the value of Cs
-1 as a surface pressure of 35 mN/m 
 
A compressibility modulus (Cs
-1) value of ~225 mN/m also suggests that DPPC-CHOL is in 
the liquid condensed (LC) phase (see section 4.4.4, above) while POPC-CHOL is in the 
liquid expanded phase (LE-LC) as indicated by the Cs
-1 75 mN/m. These results correspond 
with the previous data that demonstrated a similar rigidity for the DPPC-CHOL monolayer 
(Melik-Nubarov, Pomaz et al. 1999, Zhao and Feng 2006, Guzmán, Liggieri et al. 2013). 
Introducing cholesterol to DPPC or POPC substantially influences molecular packing within 
the monolayers, resulting in a very different molecular organization as compared to pure 
DPPC or POPC (Kim, Choi et al. 2013). The interaction of cholesterol with POPC is weaker 
and less attractive than with DPPC (Silvius 2003). The interpretation of this weak interaction 
is that the cholesterol’s higher affinity of DPPC over that for POPC depends on its alignment 
with the normal bilayer, with lower tilt angles promoted by cholesterol-cholesterol steric 
exclusion (De Joannis, Coppock et al. 2011). Also, the presence of double bonds in a cis 
conformation in POPC molecules results in induction “kink” or bend in the hydrocarbon 
System Ac 
(Å2) 
πc 
(mN/m) 
A∞ 
(Å2) 
Cs-1(mN/m) Phasea  
30 mN/m 35 mN/m 
DPPC-CHOL 29 52 41 221 229 LC 
DPPC-CHOL 
+ DNA 
41 50 53 225 325 S 
POPC-CHOL 34 41 63 74 78 LE-LC 
POPC-CHOL 
+ DNA 
35 42 67 76 86 LE-LC 
  98 
chains, rendering some of the POPC molecules less suited to packing among aligned 
cholesterols, as compared to DPPC (Rog, Murzyn et al. 2004, Wydro, Knapczyk et al. 2011, 
Jurak 2013). This results in a less condensed monolayer for the POPC-CHOL system.  
4.5.2 DPPC-CHOL and POPC-CHOL with DNA  
Isotherms obtained upon mixing DNA with the DPPC-CHOL or POPC-CHOL monolayer 
are also shown in Figure 4.5-1; the monolayer properties for the DNA/monolayer systems are 
again listed in Table 4.5-1. The addition of DNA had an impact on the DPPC-CHOL 
monolayer, where the cross-sectional area (A∞) increased from 41 Å
2 to 53 Å2. In contrast, 
the addition of DNA to the POPC–CHOL monolayer resulted in a slight increase from 63 Å2 
to 67 Å2. The compressibility modulus for both monolayers remained essentially unchanged 
with the addition of DNA. 
It has been demonstrated in the literature that DNA can interact with the model membrane 
and has some effect on cellular processes (Michanek, Kristen et al. 2010). For example, DNA 
is able to either fluidize or condense the model membrane when it interacts with a positively 
charge lipid monolayer (Antipina, Schulze et al. 2007, Chen, Kang et al. 2012, Dabkowska, 
Barlow et al. 2012, Dabkowska, Barlow et al. 2014). In our results, DNA shows a 
condensation effect on DPPC-CHOL, which is then transforms to a fluidization effect as the 
surface pressure increases (Figure 4.5-1 C).                                                                                        
DNA can potentially interact with cellular membranes, or in our case with the model 
membranes, through different types of interactions. Firstly, as a negatively charged 
polyelectrolyte, DNA can interact through electrostatic interactions with cationic lipids such 
as DOTAP or DOTMA (Langecker, Arnaut et al. 2014). In the case of DPPC-CHOL or 
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POPC-CHOL (which are zwitterionic), this interaction is expected to be negligible 
(McLoughlin, Dias et al. 2005, Michanek, Yanez et al. 2012). Secondly, solvation effects 
(i.e. hydrophobic hydration and/or hydrophobic interaction) may play a role in modulating 
the interaction(s) between DNA and the lipid monolayer. However, as a charged 
polyelectrolyte, DNA is highly hydrophilic, and these interactions are also expected to be 
negligible. Finally, DNA-based nanostructure can be attached to the lipid membrane using 
DNA conjugates with lipid, such as cholesterol, or other hydrophobic molecules (Langecker, 
Arnaut et al. 2014). DNA-lipid conjugates can be used for gene transfection to induce vesicle 
fusion or to cross-link vesicle or even cells (Chan, van Lengerich et al. 2009, Beales, Nam et 
al. 2011).  Even with the addition of multiple cholesterol modification that can be added to 
DNA, the interaction with the lipid membrane is weak and irreversible (Pfeiffer and Höök 
2004). As a result, the interactions of DNA with the model membrane are not perceived to be 
realistic because there is more of an interaction occurring with the membrane rather than 
penetration (Cárdenas, Nylander et al. 2005, Castano, Delord et al. 2009, Ahmed 2015). 
These results confirmed that the DNA is not able to penetrate in the absence of the delivery 
system. 
Interesting BAM images were obtained upon the addition of DPPC-CHOL alone at low 
surface pressure (1-3 mN/m), where the monolayer was in the G-LE phase transition (Figure 
4.5-2). The resulting domains appears to have circular or ovoid shapes. Upon compressing 
the monolayers, these domains disappear, and a uniform grey background is shown until the 
monolayer collapsed. The domains of DPPC-CHOL were then disappeared after adding CG 
to the model membrane. The reason for this disappearance is probably because the CG gets 
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adsorbed into or it is penetrated into the monolayer, which explains the fluidity of the model 
membrane (Nasir and Besson 2012).  
The addition of DNA to DPPC-CHOL resulted in small circular domains at low surface 
pressure (1-5 mN/m), which were then changed to a grey background at a high surface 
pressure (Figure 4.5-2). These domains could be attributed to the interaction between DNA 
and DPPC-CHOL through either hydrophobic interaction or local polarization (Raudino and 
Mauzerall 1986, Michanek, Kristen et al. 2010). Upon increasing the surface pressure, the 
DNA could be excluded from the monolayer and could enter into the subphase, thereby 
resulting in featureless domains similar to DPPC-CHOL alone, at high surface pressure 
(Lopes-Costa, Gámez et al. 2011). Similar to POPC-CHOL alone, the addition of DNA to 
POPC-CHOL did not show any characteristic domain formation (Figure 4.5-2). In terms of 
POPC-CHOL, the addition of DNA resulted in only small white dots as opposed to larger 
domains. These small dots likely correspond to 2-dimensional aggregates and were also 
observed at low surface pressure. This further suggests only weak interactions between the 
POPC-CHOL monolayer and DNA, possibly due to the unsaturated oleyl tail in the POPC 
lipid. The presence of the double bond results in a POPC-CHOL more fluidized monolayer, 
and therefore, the impact of the addition of DNA becomes negligible.  
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DNA+DPPC-CHOL 
B 
A 
D 
C 
DNA+POPC-CHOL DPPC-CHOL POPC-CHOL 
Figure 4.5-2: BAM Images of DPPC-CHOL (left) and POPC-CHOL (right) in the presence and absence of 
DNA at different surface pressure 
A) <1 mN/m, B) 5 mN/m, C) 30 mN/m, D) 50 mN/m for DPPC-CHOL and 40 mN/m for POPC-CHOL 
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4.5.3 Interaction of cationic gelatin with model membrane 
The addition of CG to the DPPC-CHOL membrane results in fluidization of the membrane, 
with the compressibility modulus decreasing from 221 mN/m to 182 mN/m at a surface 
pressure 30 mN/m (Figure 4.5-3 and Table 4.5-2). Upon mixing with CG, the A∞ for the 
DPPC-CHOL membrane increased from 41 Å2 up to 63 Å2, providing additional evidence for 
the fluidization of the membrane after adding CG. Recall, a small limiting area value 
corresponds to a highly packed monolayer formation (Castano, Delord et al. 2008).  
Table 4.5-2: Monolayer properties derived from isotherm and compressibility modulus plots, 
for untreated DOPC-CHOL or POPC-CHOL monolayers, and for monolayers treated with 
CG in the presence and absence of DNA 
a phase of the monolayer as determined from the value of CS
-1 at  = 35 mN.m 
The interaction of gelatin with DPPC-CHOL could arise from several potential sources 
including hydrophobic interactions, electrostatic interactions (either attractive or repulsive), 
and hydrogen bonding, among others (Fresta, Ricci et al. 2000). The presence of additional 
amino groups on the gelatin peptide backbone  from the cationization reaction will contribute 
to an increased electrostatic interaction, specifically a repulsive interaction between the 
positively charged quaternary ammonium choline head group of the phospholipids, and the 
positively charged cholamine added to gelatin (Pasenkiewicz-Gierula, Takaoka et al. 1999, 
System 
Ac (Å2) πc (mN/m) A∞ (Å2) Cs-1(mN/m) 
 
Phasea 
30 mN/m 35 mN/m 
DPPC-CHOL 29 52 41 221 229 LC 
CG+DPPC-CHOL 29 50 63 182 195 LC 
CG+DNA+DPPC-CHOL 24 54 47 92 90 LE-LC 
POPC-CHOL 34 41 63 74 78 LE-LC 
CG+POPC-CHOL 36 42 56 84 87 LE-LC 
CG+DNA+POPC-CHOL 36 42 59 85 95 LE-LC 
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Fresta, Ricci et al. 2000, Fang, Chan et al. 2001). A similar effect on DPPC monolayers was 
obtained with chitosan (Fang, Chan et al. 2001) or the nonapeptide Leucinostatin A (Fresta, 
Ricci et al. 2000). The addition of DNA to the CG/DPPC-CHOL complex also induce the 
fluidization by decreasing the compressibility modulus from 182 mN/m to 92 mN/m, 
observing a transition from LC to LE-LC phase (Figure 4.5-3 and Table 4.5-2). The 
electrostatic interaction of DNA with CG might be the reason of this fluidization. H-bonding 
between cationic polymer and DNA induces the stabilization of polyplexes (Prevette, Lynch 
et al. 2008), resulted in more effective interaction with the model membrane. These 
interactions are important to allow the CG to condense the large size of DNA and also to 
induce the permeability of the cellular membrane. 
The POPC-CHOL membrane is less rigid than DPPC-CHOL, which appears to result in 
weaker interactions with CG or CG and DNA as compared to DPPC-CHOL. It is clear from 
Table 4.5-2 and Figure 4.5-3 that the addition of CG to POPC-CHOL condensed the 
monolayer by increasing the compressibility modulus from 74 mN/m to 84 mN/m and 
decreasing the limiting sectional area from 63 Å2 to 56 Å2. This reveals that the molecules 
are more closely packed and condensed. This condensation effect might be attributed to the 
hydrophobic interaction between CG and the unsaturated lipid POPC. Since the interaction 
between POPC and cholesterol is weaker than with the DPPC, it allows the CG to directly 
interact with POPC through the hydrophobic chains of POPC, which they bend from the 
cholesterol due to the presence of the double bond, resulting in more condensed molecules. 
The addition of DNA did not cause much change in the system with the POPC-CHOL  
  104 
 
Figure 4.5-3: Isotherms (A, B) and compressibility modulus plots (C, D) of the monolayer 
alone, monolayer and CG, and monolayer, CG, and DNA. DPPC-CHOL (A, C) and POPC-
CHOL (B, D). 
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monolayer. It is apparent that the compressibility modulus and limiting area remained almost 
the same for both CG/POPC-CHOL system in the presence or absence of DNA.  
BAM images of CG combined with either both DPPC-CHOL or POPC-CHOL show a grey 
background with no distinctive domains at all surface pressures. This means that CG has an 
impact on the monolayers, resulting in changing the shapes of domains for both DPPC-
CHOL and POPC-CHOL (Figure 4.5-4). This impact can be explained through the 
compressibility moduli and limiting areas (Table 4.5-2), which showed that CG has a 
fluidization and condensation effect on both DPPC-CHOL and POPC-CHOL respectively. 
Bead-like domains were observed in the DPPC-CHOL monolayer after the addition of DNA 
to CG at low surface pressure. These bead-like domains likely resulted from a reorganization 
of DPPC and CHOL in the lipid monolayer, possibly as means to reduce the solvation energy 
for the DNA:CG complexes, which due to charge neutralization, are expected to be quite 
hydrophobic. This reorganization is consistent with the fluidization of the monolayer 
observed from the isotherm, as described above. The addition of DNA to CG/POPC-CHOL 
complex did not result in any reorganization similar to what was observed with CG/POPC-
CHOL alone. This demonstrates weaker interaction of DNA with POPC-CHOL either in the 
presence or absence of CG. Upon further compression, a featureless homogeneous grey film 
with no domains was observed in the whole system in both DPPC-CHOL and POPC-CHOL. 
From the above, we conclude that CG has a fluidizing effect on DPPC-CHOL, but not on 
POPC-CHOL. Furthermore, DNA influences the interaction with the membrane through its 
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strong interaction with CG, which enhances the stability of the delivery system, resulting in 
more fluidized effect, particularly with DPPC-CHOL. 
 
Figure 4.5-4: BAM Images of CG with DPPC-CHOL (left), and POPC-CHOL (right) in the 
presence and absence of DNA at different surface pressure.  A) <1 mN/m, B) 5 mN/m, C) 30 
mN/m, D) 50 mN/m for DPPC-CHOL and 40 mN/m POPC- CHOL. CG: cationic gelatin. 
 
4.5.4 DPPC-CHOL and POPC-CHOL with Pluronics, CG, and DNA 
Different Pluronics in combination with DPPC-CHOL monolayers have been studied by 
others, in an attempt to understand the effect of basic surface characteristics based on the 
number of EO and PO, as well as the molecular weight (Chang, Chang et al. 2008). A 
CG+DPPC-CHOL CG+DNA+DPPC-CHOL 
A 
B 
D 
C 
CG+POPC-CHOL CG+DNA+POPC-CHOL 
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previous study conducted by Change et al. (Chang, Chang et al. 2008) studied different 
Pluronics with varying EO and PO units. The results indicated that while the number of EO 
monomers of the Pluronic increased, the area per molecule also increased especially when 
the surface pressure increased with significant differences between Pluronics. The same 
study explained that the area per molecule was larger when the number of PO monomers of 
Pluronic was also large at fixed EO monomers. Lastly, the study compared Pluronics with 
different molecular weights (MW), at a constant weight percentage of PEO chains. The 
authors found that there was a linear relationship between MW and the area per molecules. A 
larger molecular weight obtained higher area per molecules (Chang, Chang et al. 2008).  
Pluronics are amphiphilic structures that contain both hydrophilic (PEO) and 
hydrophobic (PPO) blocks. It is believed that the interaction of Pluronics with DPPC is 
influenced by PEO chains. When the compression begins, most of the PEO enters the 
subphase while the PPO remains on the interface (Chang, Chang et al. 2008). This is due to 
the "squeezed-out" phenomenon (Weingarten, Magalhaes et al. 1991, Maskarinec, Hannig et 
al. 2002, Wu, Majewski et al. 2004, Chang, Lin et al. 2005), which was noted earlier by 
Weingarten et al. in 1991(Weingarten, Magalhaes et al. 1991). The authors revealed that 
when Pluronic F68 mixed with the model membrane (DPPC), the Pluronic squeezed out of 
the lipid monolayer at a high surface pressure (≥ 35 mN/m) (Maskarinec and Lee 2003).  
Cholesterol is known to change the behaviour of the membrane by reducing passive 
permeability, increasing the mechanical strength, and manipulating the function of the 
membrane enzymes (Yeagle 1985, Ohvo-Rekilä, Ramstedt et al. 2002). The addition of 
cholesterol to DPPC monolayers changed the interaction behaviour of Pluronics with the 
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membrane (Chang, Chang et al. 2008). The addition of cholesterol to DPPC did not affect the 
penetration kinetics for the copolymers. Although PPO may have some hydrophobic 
interaction with cholesterol, this interaction was not strong enough to affect the penetration 
(Chang, Chang et al. 2008).  
At low surface pressure, when the monolayer is not packed, the interaction between 
cholesterol and DPPC is expected to be weak. Therefore, the penetration of Pluronics into the 
monolayer is enhanced through hydrogen bonding between cholesterol and the PEO moieties 
of the Pluronics (Mpofu, Addai-Mensah et al. 2003, Anselmo, Sassonia et al. 2006) . This is 
obvious from our results, where the addition of Pluronic results in fluidization of the 
monolayer at low surface pressure, seen from the decrease in the compressibility modulus of 
DPPC-CHOL from 221 mN/m to less than 200 Nm/m for all Pluronics and increasing the 
limiting cross-sectional area from 41 Å2 to ~ 54 Å2 (Table 4.5-3), which indicates another 
parameter of fluidization. Conversely at high surface pressure, when the monolayer is closely 
packed and the interaction between cholesterol and DPPC is very strong, the penetration of 
Pluronics is inhibited. In pure cholesterol monolayers, the hydrogen bond that exists between 
3β- hydroxyl group of cholesterol and ether oxygens (Lewis base) of PEO chains result in 
deep penetration of Pluronics especially those with long PEO segments (Chang, Chang et al. 
2008). 
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Table 4.5-3: Monolayer properties derived from isotherm and compressibility modulus plots, 
for untreated DOPC-CHOL or POPC-CHOL monolayers, and for monolayers treated with 
CG and Pluronics in the presence and absence of DNA. 
a phase of the monolayer determined from the value of CS-1 at  = 35 mN/m.  
 
In our results, hydrophilic Pluronics F87 and F108 (which have PEO blocks of 122 and 156 
EO groups, respectively), resulted in a compressibility modulus at 30 mN/m equal to179 and 
174 mN/m and limiting cross-sectional areas 32 Å2 and 50 Å2 respectively. On the other 
hand, hydrophobic Pluronics L44 and P103 (with PEO blocks of 20 and 33 EO groups, 
respectively) resulted in a compressibility modulus of 198 and 195 mN/m and a limiting 
System Ac 
(Å2) 
πc 
(mN/m) 
A∞ 
(Å2) 
Cs-1(mN/m) Phasea 
30 mN/m 35 mN/m 
DPPC-CHOL Monolayer 
DPPC-CHOL 29 52 41 221 229 LC 
L44+DPPC-CHOL 36 52 51 198 264 S 
L44+CG+DPPC-CHOL 34 51 65 156 198 LC 
L44+CG+DNA+DPPC-CHOL 33 51 55 163 273 S 
F87+DPPC-CHOL 20 55 32 179 263 S 
F87+CG+DPPC-CHOL 20 54 43 116 109 LC 
F87+CG+DNA+DPPC-CHOL 22 53 37 149 227 LC 
P103+DPPC-CHOL 39 51 54 195 221 LC 
P103+CG+DPPC-CHOL 34 50 69 135 117 LC 
P103+CG+DNA+DPPC-CHOL 29 53 62 159 192 LC 
F108+DPPC-CHOL 30 52 50 174 250 S 
F108+CG+DPPC-CHOL 40 51 66 110 104 LC 
F108+CG+DNA+DPPC-CHOL 33 51 63 160 117 LC 
POPC-CHOL Monolayer 
POPC-CHOL 34 41 63 74 78 LE-LC 
L44+POPC-CHOL 27 45 57 83 76 LE-LC 
L44+CG+POPC-CHOL 26 45 60 78 84 LE-LC 
L44+CG+DNA+POPC-CHOL 27 44 59 81 87 LE-LC 
F87+POPC-CHOL 29 46 50 102 107 LC 
F87+CG+POPC-CHOL 30 45 63 82 81 LE-LC 
F87+CG+DNA+POPC-CHOL 31 45 55 94 94 LE-LC 
P103+POPC-CHOL 30 42 62 76 84 LE-LC 
P103+CG+POPC-CHOL 27 42 72 68 50 LE-LC 
P103+CG+DNA+POPC-CHOL 25 42 66 74 78 LE-LC 
F108+POPC-CHOL 26 41 64 76 77 LE-LC 
F108+CG+POPC-CHOL 27 40 76 61 50 LE-LC 
F108+CG+DNA+POPC-CHOL 30 42 65 76 78 LE-LC 
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cross-sectional area 51 Å2 and 54 Å2 respectively. It is noticed that the limiting cross-
sectional areas are very similar for all Pluronics except for Pluronic F87 (likely due to its 
greater solubility in water). Due to the squeeze out phenomenon, at high surface pressure, 
there are very few PEO units that remain associated with the monolayer and thus, the DPPC 
and cholesterol molecules become more closely packed, which leads to penetration inhibition 
for the Pluronic (Maskarinec and Lee 2003). Our results indicate that there is a deep 
penetration for Pluronics at low surface pressure, but this penetration is inhibited when the 
surface pressure has increased.   
Based upon both the isotherms (see Table 4.5-3 for the area parameters) and the 
compressibility modulus values, there is no apparent interaction between the POPC-CHOL 
monolayer on either P103 or F108. On the other hand, L44 and F87 increased the 
compressibility modulus from 74 mN/m to 83 and 102 mN/m respectively, while the minimal 
sectional area decreased from 63 Å2 to 57 and 50 Å2 for both Pluronics respectively. This 
suggests that the membrane became more condensed; an effect which mirrors that 
seen for the addition of CG to the POPC-CHOL monolayer (see section 4.5.3). 
Nevertheless, the changes in membrane fluidity are not remarkable and in particular 
do not result in a change in the molecular phase. 
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Figure 4.5-5: Isotherms (A, B) and compressibility modulus plots (C, D) of the monolayer alone, 
and monolayer and Pluronics. DPPC-CHOL (A, C) and POPC-CHOL (B, D). 
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BAM images of the DPPC-CHOL monolayer upon the addition of Pluronics shows 
distinctive domains (Figure 4.5-6). These domains are circular or ovoid in shapes, and they 
are observed at low surface pressure (1-5 mN/m), where greater interaction between the 
molecules within the monolayer and the Pluronics appear to occur. Pluronics P103 and F108 
(which have the same unit of PPO (~ 50)) do show domains at low surface pressure. 
However, these domains tend to disappear earlier than in L44 and F87. This might be 
attributed to PPO blocks, which they can interact with cholesterol through either hydrophobic 
or hydrogen bonding, or both (Anselmo, Sassonia et al. 2006). Consistent with the isotherm, 
it is clear from the BAM images that most of the interactions between Pluronics and the 
model membrane take place at low surface pressure when both PEO and PPO units coexist. 
Once the surface pressure increases, most of the PEO units enter into the subpahse and leaves 
the PPO units on the surface, resulting in lower interaction and thus, fewer domains.  
Images of POPC-CHOL with Pluronics show some domains that were formed at low surface 
pressure, particularly for Pluronics L44 and F87; although the generally featureless images 
obtained at most surface pressures regardless of polymer are consistent with a relatively 
homogeneous LE or LE-LC phase. The fact that the domains are observed for L44 and F87, 
but not for P103 and F108, is consistent with the discussion above, where L44 and F87 were 
observed to induce the condensation of the monolayer seen from the increase in the 
compressibility modulus and decrease in the limiting area (Table 4.5-3 and Figure 4.5-5).  
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DPPC-CHOL 
POPC-CHOL 
DPPC-CHOL 
POPC-CHOL 
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DPPC-CHOL 
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Figure 4.5-6: BAM images of all Pluronics with DPPC-CHOL and POPC-CHOL at different surface 
pressures.  A) <1 mN/m; B) 5 mN/m; C) 30 mN/m; D) 50 mN/m for DPPC-CHOL and 40 mN/m for 
POPC-CHOL. 
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When CG was added to the Pluronics, and both were added to the model membrane systems, 
the fluidization of the model membrane was induced, larger than the CG alone, as observed 
by a decrease in the compressibility modulus at 30 mN/m, independent of which Pluronic is 
used (Table 4.5-3). Correspondingly, the limiting areas obtained for all CG/Pluronic mixtures 
increased after adding CG for all Pluronics except for F87 (due to the greater solubility as 
mentioned previously), a further indication of fluidization. This increase in fluidization is 
attributed to different interactions occurring between CG and Pluronic with DPPC-CHOL. 
The interaction between CG and Pluronics is noticeable when the fluidization of the 
membrane increased after adding CG compared to the Pluronics alone. This interaction 
between CG and Pluronics is referred to hydrophobic interaction (Schuetze and Mueller-
Goymann 1993), which is suggested to be a very strong interaction. The addition of 
CG/Pluronic complex to the model membrane may have resulted in a greater size, which 
somehow makes the Pluronic to exclude the PPO block that was inserted into the membrane, 
resulting in minimizing the water contact. Another interaction which occurs between CG and 
Pluronics is through the formation of hydrogen bonding. This interaction affects the 
hydrophilic part of Pluronics, which results in a more fluidized membrane with hydrophilic 
Pluronics (F87 and F108) compared to hydrophobic Pluronics (L44 and P103).   
When the DNA was added to Pluronic/CG complex, the compressibility modulus increased 
with subsequent decreases in limiting areas for all Pluronic subsequently (Table 4.5-3 and 
Figure 4.5-7). It is apparent that DNA reduces the fluidization of membrane and results in the 
molecules becoming more closely packed. As mentioned previously, DNA can have either a 
fluidization or condensation effect, depending upon the nature of the monolayer (Antipina, 
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Schulze et al. 2007, Chen, Kang et al. 2012, Dabkowska, Barlow et al. 2012, Dabkowska, 
Barlow et al. 2014). In our project, the DNA has a condensation effect when is added to 
Pluronic/CG complex.  
In terms of POPC-CHOL, CG induces the fluidization of the model membrane by decreasing 
the compressibility moduli and increasing the limiting areas for all Pluronics. It is clear from 
Table 4.5-3 that CG induced the fluidity of Pluronics that have longer hydrophobic units 
(P103 and F108) than Pluronics, which have shorter hydrophobics units (L44 and F87). This 
explains that hydrophobicity plays an essential role in the fluidity of model membrane 
POPC-CHOL.  
The addition of DNA to the CG/Pluronic complex reduces the fluidization of the monolayers 
by increasing the compressibility moduli and decreasing the limiting areas (Table 4.5-3, 
Figure 4.5-7), which makes the molecules closely packed either with POPC-CHOL or DPPC-
CHOL.  These results confirm the condensation effect of DNA in our system.       
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Figure 4.5-7: Isotherms (A, B) and compressibility modulus plots (C, D) of the monolayer alone, 
and monolayer with Pluronics, CG, and DNA. DPPC-CHOL (A, C) and POPC-CHOL (B, D). CG: 
Cationic gelatin.  
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Distinctive domains were observed when DPPC-CHOL was mixed with the Pluronic and CG 
either in the presence or absence of DNA (Figure 4.5-8). These domains are usually seen 
between the surface pressure 1-5 mN/m and they are different from CG/DNA domains alone, 
indicating the interaction between CG and Pluronics. The large domains that are observed 
might be referred to the model membrane or Pluronics, while the small white dots might be 
referred to CG. This confirms that when the surface pressure increases to 5 mN/m, the large 
domains disappeared, and what is left are only the white dots (with some lines), particularly 
in hydrophobic Pluronics L44 and P103. These shapes at surface pressure 5 mN/m might 
correspond to the hydrophobic interactions between Pluronic and CG, which are previously 
explained in the isotherm results. As already mentioned above, the domains of DPPC-CHOL 
are observed in surface pressure between 1-3 mN/m, which confirm that the white dots with 
lines are related to CG and Pluronics at surface pressure 5 mN/m. DNA did not show 
distinctive domains when interacting with DPPC-CHOL, indicating that the DNA may have 
a condensation effect only on the model membrane rather than with any other interaction. 
Upon the compression of the barriers, the domains gradually vanished until completely 
disappearing at a surface pressure of around 30 mN/m. These results are in agreement with 
the results including only Pluronic and model membrane alone, or CG and model membrane 
alone, indicating that there is a weak interaction between the Pluronics and the model 
membrane at high surface pressure. These outcomes were also mentioned in the isotherm 
results above.  
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Regarding the POPC-CHOL monolayer, featureless images were observed when the 
monolayer interacted with either Pluronic, CG, or DNA, at low or high surface pressure 
(Figure 4.5-8). This is due to the fluidization of the POPC-CHOL, which makes the 
interaction weaker than that of DPPC-CHOL. All systems demonstrated exactly the same 
domains. The systems showed small domains at low surface pressure, and then, when the 
surface pressure increased, the small domains disappeared, and were replaced by a grey 
background, indicating that all systems get fluidized when they interact with POPC-CHOL. 
L44 was the only Pluronic that showed a slightly greater domain formation. These domains 
may be formed due to the hydrophobicity, and the short number of EO units, which makes 
the PO units interact directly with POPC-CHOL at low surface pressure. These results are in 
agreement with the isotherms of the POPC-CHOL with the delivery system. The change in 
compressibility modulus, cross-sectional area, and molecular area at collapse is small and not 
remarkable. 
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CG+DNA+DPPC-
CHOL 
CG+DNA+POPC
-CHOL 
CG+DNA+DPPC
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Figure 4.5-8: BAM images of all Pluronics with CG and DNA with DPPC-CHOL and POPC-CHOL at 
different surface pressure. A) <1 mN/m, B) 5 mN/m, C) 30 mN/m, D) 50 mN/m for DPPC-CHOL and 40 
mN/m for POPC-CHOL.  CG: cationic gelatin  
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4.6 Summary 
The Langmuir monolayer study, combined with Brewster’s angle microscopy at the air/water 
interface, were conducted to in order to gain a better understanding of the interaction of our 
transfection complexes with simple models of a biological membrane. The DPPC-CHOL 
monolayers were found to be more rigid compared to the POPC-CHOL monolayers, 
consistent with literature results, as well as expectations based upon molecular structure. The 
addition of CG, the key component in our proposed transfection formulations, resulted in an 
increase in the fluidity of the monolayer for the DPPC-CHOL monolayers, and a decrease in 
fluidity for the POPC-CHOL.  This is attributed to the electrostatic and the hydrophobic 
interaction of CG with the monolayers. The addition of DNA, alone (i.e., in the absence of 
CG or Pluronic) induced rigidity in both monolayers, likely due to the electrostatic and 
hydrophobic interactions with the lipid monolayer, however these interactions are expected 
to be negligible. The combination of CG and DNA again imparted a small degree of fluidity 
in both monolayers, due to the electrostatic interaction of DNA with CG and model 
membrane.  
Ultimately, the addition of the complete CG/DNA/Pluronic formulation was observed to 
weakly induce the fluidization of the DPPC-CHOL and POPC-CHOL monolayers compared 
to CG/DNA alone. The extent to which fluidization was observed was dependent upon the 
Pluronics’ structures, which have different hydrophilic and hydrophobic units. The strong 
hydrophobic interaction between Pluronic and CG allowed the DNA to induce the 
condensation of DPPC-CHOL, however this condensation effect was minimal, and did not 
affect the interaction with the model membrane. The results highlighted the fact that our 
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formulations interacted effectively and enhanced the permeability of the model membrane 
DPPC-CHOL, therefore and demonstrating a minimal effect on POPC-CHOL. 
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 Transfection Efficiencies and Cell Viability of Gelatin/Pluronic/DNA 
System in COS-7 Cells  
5.1 Introduction  
A positive charge was introduced onto the surface of gelatin nanoparticles to produce 
cationic gelatin (CG). Positive charge is very significant to interact with the negative charge 
of DNA and the cell membrane. Gelatin was selected because it has several advantages, as 
mentioned in Chapter 1. In addition, the positive results obtained by using gelatin as a 
delivery system encouraged us to use it in this project. In order to improve the transfection 
efficiency of CG/DNA complex, Pluronic block copolymers were added to protect the 
CG/DNA complex from degradation and to prolong the circulation time of the delivery 
system. Gemini surfactant (GS) 16-3-16 was also used in order to improve the transfection 
efficiency of CG/DNA complex. CG/DNA complex, along with GS and four different 
Pluronics (L44, F87, P103, and F108), were tested in vitro to evaluate the transfection 
efficiency and cell viability in COS-7 cells. COS-7 cells (ATCC® CRL165™) are fibroblast-
like cells derived from African monkey kidney tissue. COS are adherent cells carrying SV40 
genetic material and obtained by immortalizing CV-1 cells (Jensen, Girardi et al. 1964, 
Gluzman 1981). The combination of fibroblast-like growth and SV40 make COS-7 a great 
choice for transfection experiments using plasmid DNA and mutation to the SV-40 virus. 
COS-7 also possesses easily-transfected cells,  which is the reason it was selected for our 
experiments.  
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5.2  Materials  
Gelatin type A Protein content 81% Bloom ~300 (Refer to chapter 3 for the gelatin and 
cationic gelatin). Gemini surfactant 16-3-16 was synthesized and purified in our lab 
according to published methods (Wettig and Verrall 2001, Wang and Wettig 2011). Gibco 
DMEM high glucose, pyruvate, L-glutamine Phenol Red Sodium Pyruvate, and Fetal Bovine 
Serum (FBS) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
Dulbecco’s Phosphate Buffered Saline (DPBS), and 0.25% Trypsin- EDTA (1X) were 
purchased from Gibco by Life Technologies. COS-7 (ATCC® CRL-1651TM) African green 
monkey kidney fibroblast-like was purchased from the American Type Culture Collection 
(ATCC) in Manassas, VA, USA. JetPEITM cationic polymer transfection reagent was 
purchased from PolyPlus. Tryple Express reagent (no phenol red) (1X) was purchased from 
Life-Technology Inc. Nunc Cell Culture Treated multi-dishes, 6-well, BD 5 mL polystyrene 
round bottom test tube (FACS tube), Propidium iodide (PI) 95%, and Gibco Opti-MEM™ I 
Reduced Serum Medium (no phenol red) were purchased from Fisher Scientific. Highly-
purified Millipore-Q water (18 mΩ cm and 72.6 mN/m at 20°C) was obtained from a Milli-Q 
filtration system in the School of Pharmacy, University of Waterloo.  
5.3 Method 
5.3.1 Transfection efficiency and cell viability studies  
COS-7 cells (ATCC) were grown to 70-80% confluency in 75-cm2 tissue culture flasks in 
DMEM-high glucose medium, supplemented with 10% FBS. Cells from passage number 5 to 
15 (0.5 x 106 COS-7 cells) per well, in DMEM high glucose media with FBS, were seeded in 
a 6-well plate, one day before the transfection, in order to allow the cells to adhere to the 
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bottom of the wells. The DMEM (+FBS) medium was changed to DMEM medium (without 
FBS) one hour prior to transfection. The cells were then transfected with pTGINF-GFP 
plasmid using jetPEI® (Polyplus-transfectionTM) as a positive control. For each well, 2 μg of 
plasmid was used for all formulations, except for the one with positive control. The 
transfection method of jetPEI® followed the manufacturer’s protocol and was optimized for 
the COS-7 cells. 3 μg plasmid was briefly mixed with 6 μL jetPEI® reagent in 100 µL 150 
mM NaCL and was incubated at room temperature for 15 to 30 minutes. After incubation, 
the jetPEI®/DNA mixture was added dropwise to the treated cells covered with 2 mL of 
serum-free medium.  
GS and CG were mixed with the plasmid DNA separately in Opti-Mem, and were incubated 
at room temperature for 15 minutes. The required amount of the Pluronic solution was then 
added, and the mixture was incubated for a further 30 minutes. The mixture was then added 
dropwise to the treated cells. After five hours, the transfection mixture in each well was 
replaced with 2 mL of DMEM (+FBS) medium, and the cells were then incubated for 48 
hours in a tissue culture incubator at 37°C with 5% CO2. Transfections experiments were 
conducted using the following conditions (Table 5.3-1). 
 
 
 
 
                                                                                                                                                           
  125 
Table 5.3-1: Conditions used for transfection experiments 
Condition name  Condition used  
Preparation medium  Opti-Mem 
Serum  Serum-free 
Concentration of DNA  2 µg for cationic gelatin-Pluronic & 3 µg 
for the positive control 
Incubation time after transfection 5 hours  
Incubation time after changing the medium 
to perform FACS  
48 hours  
Ratios of prepared nanoparticles From 1: 20-300 of DNA to CG 
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5.3.2 Fluorescence-activated cell sorting (FACS) 
Two days post-transfection, 2 mL of DMEM (+FBS) medium in each well was aspirated, and 
1 mL of Tryple Express®/Trypsin was added to detach the cells. Then, 3 mL of DMEM 
(+FBS) medium was added to neutralize the Tryple Express/ Trypsin. Afterward, the cells 
were collected in 5 mL fluorescence-activated cell sorting (FACS) tubes and centrifuged at 4 
°C at 125 ×g for 10 minutes. The GFP expressing cells were then washed twice with a 
phosphate buffered saline (PBS) after centrifugation and were suspended in 350 µL of PBS 
for FACS analysis. FACS measurements were carried out using a BD FACSAria Fusion 3-
laser instrument in the Department of Biology at the University of Waterloo. Just prior to 
analysis, the samples were stained using propidium iodide (PI) in order to determine the cell 
viability, along with the transfection efficiency. Transfection efficiency was presented 
corresponding to the percentage (%) of cells displaying the EGFP expression out of 10,000 
cells. Cell viability was expressed as the percentage (%) of dead cells, determined by PI 
staining. The transfection formulations were prepared according to Table 5.3-2. 
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Table 5.3-2: Transfection formulations template for each well 
Formulation Vplasmid VGS VCG VPluronic Vmedia VJetPEI Vwell 
Jet+DNA 16.6 (3 µg)    400 12 µL 200 
Plasmid Only 6.6(2.4 µg)    300  250 
GS only  24    300  250 
Gelatin only   40   300  250 
Gelatin+DNA 6.6  40  300  289 
GS+DNA (2 µg) 1:10 6.6 24    300  276 
GS+L44+DNA (2 µg) 6.6 24  47.4 300  315 
GS+F87+DNA (2 µg) 6.6 24  42 300  310.5 
GS+F108+DNA (2 
µg) 
6.6 24  18 300  290.5 
GS+P103+DNA (2 
µg) 
6.6 24  9 300  283 
CG+L44+DNA 6.6 24 40 47.4 300  328 
CG+F87+DNA 6.6 24 40 42 300  324 
CG+F108+DNA 6.6 24 40 18 300  304 
CG+P103+DNA 6.6 24 40 9 300  296 
GS+CG+L44+DNA 6.6 24 26.88 47.4 300  337.4 
GS+CG+F87+DNA 6.6 24 26.88 42 300  333 
GS+CG+F108+DNA 6.6 24 26.88 18 300  313  
GS+CG+P103+DNA 6.6 24 26.88 9 300  305  
NOTE: ALL volumes are in µL; VPlasmid corresponds to the volume of plasmid stock solution; VGS corresponds 
to the volume of gemini surfactant stock solution; VCG corresponds to the volume of cationic gelatin stock 
solution; VPluronic corresponds to the volume of pluronic stock solution; Vmedia corresponds to the volume of 
media; and VJetPEI corresponds to the volume of JetPEI transfection mixture. All components were combined, 
and wells were then treated with a volume of solution corresponding to Vwell. 
5.4 Statistical Analysis  
All the presented data in the in vitro transfection studies section correspond to the mean of 
three determinations; the results were compared using One-Way Analysis of Variance 
(ANOVA); test significance was accepted at P <0.05. 
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5.5 Results and Discussion 
5.5.1 Particle size and zeta potential  
In this project, we were able to design a nanoparticle gene delivery system comprised of CG, 
DNA, and Pluronic block copolymers. The particle size and zeta potential of these systems 
were measured and demonstrated small particle size and positive zeta potential values for all 
formulations (Figure 5.5-1). Nanoparticles were prepared at a ratio of 1:20 (w/w) of DNA to 
CG and demonstrated the lowest diameter with the greatest positive charge. Adding more CG 
to the DNA did not change the positive value of the complex and led to larger-sized particles 
(Chapter 3). The particle size and zeta potential for nanoparticles containing the four 
Pluronics (L44, F87, P103, and F108) at concentrations corresponding to 0.1×CMC, 
1×CMC, and 2×CMC were also measured (Figure 5.5-1).  It is clear from the data that all 
formulations containing Pluronic demonstrated small particle sizes (~ 140-170 nm) and 
positive zeta potentials. Not surprisingly, the zeta potential decreased with an increased 
concentration of the Pluronics due to shielding provided by the neutral Pluronic copolymer 
adsorbed to the surface of the CG/DNA complex. P103 was a clear exception to this 
behavior, where the zeta potential increased with the increased P103 concentration. While 
both L44 and P103 are similarly hydrophobic in nature, P103 is much larger with a very low 
CMC. It is possible that the interactions between the CG/DNA complex and P103 are not 
sufficiently strong to provide sufficient protection of the hydrophobic PPO segment from 
water, and that as concentration of P103 increases, there is a preference for it to dissociate 
from the CG/DNA complex and form its own micellar aggregates that contain only P103.  
This would have a net result of increasing the zeta potential, as observed in our data.  
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Figure 5.5-1: Particle size and zeta potential of nanoparticles containing cationic gelatin, 
DNA, and the indicated Pluronic at concentrations corresponding to 0.1×CMC, 1×CMC, and 
2×CMC. Bars represent particle size, dots represent zeta potential. Samples were measured in 
triplicate, errors are equal to standard deviation.  
 
5.5.2 Transfection efficiency and cell viability of cationic gelatin/Pluronic/DNA 
Initial transfection studies were carried out using nanoparticles prepared using only DNA and 
CG at a ratio of 1:20 (w/w) DNA to CG. No transfection was observed using this system, in 
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contrast to the results obtained by Kaul and Amiji (Kaul and Amiji 2005), who found that 
gelatin nanoparticles were observed around the nucleus six hours after incubation. Our initial 
incubation time was five hours; upon increasing it to the six hours used by Kaul and Amiji, 
the same lack of transfection was observed. The experiment was subsequently run using 
different ratios of DNA to CG in order to determine if a 1:20 ratio was sufficient. Ratios of 
1:20, 1:50, 1:100, 1:150, 1:200, 1:250, and 1:300 were all examined; unfortunately, all these 
concentrations failed to show any significant gene expression (Figure 5.5-2). 
At this point, it was decided to re-examine the particle size and zeta potential of the 
nanoparticles, this time in buffer so as to determine if buffer had an impact on the 
formulations. The particle size of the formulations prepared in buffer were both larger and 
exhibited multiple peaks (corresponding to multiple populations of particle sizes) compared 
to those prepared in water, indicating aggregation of the nanoparticles in the presence of 
Figure 5.5-2: Transfection efficiency in % (expressed in terms of EGFP expression of live 
cells) (A), and cell viability in % (expressed in terms of dead cells stained by PI) (B) of 
cationic gelatin and DNA using different w/w ratios in COS-7 cells. 
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buffer (Figure 5.5-3). As a polypeptide, gelatin is very sensitive to pH, due in part to its 
amino acid composition; this might be the reason for the observed aggregation in the 
presence of buffer (Misra, Meher et al. 2016). Even though the CG/DNA nanoparticles 
possessed substantial positive charge in water, this was largely neutralized in buffer, even for 
nanoparticles containing the highest amount of CG (1:300). It is likely that the lack of 
transfection can be attributed to aggregation in the presence of buffer; confocal microscopy 
studies would be useful to confirm this. The one positive result in these initial transfection 
studies is that even at the high DNA:CG ratios (i.e., 1:300), low cell toxicity was observed; 
however, with the lack of transfection, this observation is not particularly useful. 
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Figure 5.5-3: Particle size (A) and zeta potential for nanoparticles containing different ratios 
of DNA to cationic gelatin in water (black) and buffer (grey). Samples were measured in 
triplicate, errors are equal to standard deviation.  
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While the above results clearly suggest that aggregation of the DNA/CG complexes was the 
reason for the lack of transfection, it is also possible that cholamine may not have been the 
proper agent to cationize gelatin, as it may interact poorly with the DNA, thus resulting in 
weak complexation. Similar results for gelatin nanoparticles modified with polyamines, such 
as spermidine and spermine, also failed to efficiently complex pDNA in buffer (Zwiorek 
2006). Cationic agents with a stronger positive charge, such as PEI, might be required to 
complex the DNA and to facilitate the passage of the negatively-charged cellular membrane 
(Kuo, Huang et al. 2011). The batch of gelatin nanoparticles itself is probably another factor 
that could affect the transfection efficiency. Zwiorek (Zwiorek 2006) tried different batches 
of gelatin with different size and zeta that failed to adsorb the DNA, even when the batches 
were modified with cholamine. Consequently, loading nucleic acids on the surface of CG 
nanoparticles could not be generalized. What successfully worked with a certain nucleic acid 
was not necessarily successful with another. Based on these outcomes, we decided to add 
gemini surfactant (GS) to our formulations. 
5.5.3 Gemini surfactant and cationic gelatin 
As mentioned in Chapter 1, GSs can form micelles at low critical micelle concentrations 
(CMC). GS also possesses two positive charges, giving rise to strong electrostatic 
interactions with plasmid DNA as well as with the cellular membrane, which contributes to 
their effectiveness as transfection vectors.  In this project, it was thought that adding GS 
would improve the transfection efficiency of CG. GS 16-3-16 was chosen due to the previous 
results of transfection efficiency obtained in previous studies, both in our group and among 
  133 
other teams (Foldvari, Badea et al. 2006, Badea, Wettig et al. 2007, Wang, Kaur et al. 2013, 
Madkhali 2014).  
The first detectable gene expression was seen with GS at the ratio of 1:10 DNA to GS. CG 
was then added to determine if it would increase the transfection efficiency of the 16-3-16 
surfactant. Four different w/w ratios of GS to CG were tested (1:1, 1:2, 1:3, and 1:4). The 
results revealed that as more CG was added, the lower the transfection became, while cell 
viability increased (Figure 5.5-4). In order to understand these results, examination of 
particle size and zeta potential were conducted for GS/CG complex in buffer.  
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The results showed that adding CG to GS enhanced the aggregation of the complexes. 
Particle size increased after adding CG from 110 nm to ~ 1800 nm (Figure 5.5-5), while a 
corresponding decrease in zeta potential (i.e., a decrease in the positive charge of the 
complexes) was seen when increasing the amount of CG, which probably led to antagonistic 
interaction between GS and CG. It would seem that the addition of the CG results in a 
shielding or partial neutralization of the positive that exists on the surface of the GS micelles, 
suggesting that the CG is localized at or near the surface of the surfactant aggregates. Once 
the surface charge is reduced, increased aggregation of the complexes can occur (Figure 5.5-
6).  It is this aggregation that is the likely source of the low transfection efficiencies observed 
for the GS/CG/DNA complexes.  
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Figure 5.5-4: Transfection efficiency in % (expressed in terms of EGFP expression of live 
cells) (A), and cell viability in % (expressed in terms of dead cells stained by PI) (B) of 
different w/w ratios of gemini surfactant and cationic gelatin (1:1, 1:2, 1:3, and 1:4) in 
COS-7 cells. GS is significantly different to CG at all ratios (***P<0.0001). 
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Figure 5.5-5: Size (A) and Zeta potential (B) of gemini surfactant and cationig gelatin at 
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equal to standard deviation.  
 
Figure 5.5-6: Schematic illustration of the interaction between gemini surfactant and cationic 
glelatin.  Gelatin forms a shield around the gemini surfactant, which results in aggregation and 
decreases the positive charge of gemini surfactant. 
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The last step of the transfection studies was to add Pluronics to the transfection complexes. It 
was believed that Pluronics could protect the DNA from degradation and increase the 
circulation time in vivo; that was, however, assuming that the CG was able to transfect DNA, 
which as discussed above – however, it was not. Figure 5.5-7 shows the combined results of 
transfection experiments using GS/DNA, CG/DNA, CG/GS/DNA, CG/Pluronic/DNA, and 
CG/GS/Pluronic/DNA complexes. Not surprisingly, the addition of Pluronics to CG did not 
result in transfection. Given that Pluronics are neutral polymers, it would not be expected that 
their addition would improve the transfection of the weak CG. 
 
Figure 5.5-7: Transfection efficiency in % (expressed in terms of EGFP expression of live cells) 
(A), and cell viability in % (expressed in terms of dead cells stained by PI) (B) of different 
combinations of delivery system in COS-7 cells. NG represents native gelatin, CG represents 
cationic gelatin, and GS represents gemini surfactant. GS alone with DNA is significantly different 
to all other nanocomplexes containing Pluronics, CG, or both (***P<0.0001). 
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When added to the GS/DNA complexes, the Pluronics decreased the transfection efficiency 
of the GS, similar to what was observed by the addition of CG to the GS/DNA complexes 
(see discussion above). The Pluronic is expected to adsorb at the surface of the GS/CG/DNA 
complexes (in particular the EO segments), further shielding the positive charge of the 
complexes, again likely resulting in increased aggregation that then decreases the ability of 
the complexes to transfect the DNA.  
One positive result seen in the transfection studies relates to cell viability. CG showed 
excellent cell viability in all systems; although this is most likely due to the weak cationic 
charge that seems to be imparted to the gelatin using our method. As it is known that 
cytotoxicity increases with increased positive charge (i.e., an increasing number of 
quaternary ammonium groups) (Vieira, Hartmann et al. 2008, Garcia, Kaczerewska et al. 
2016), it is likely that this may not be the case where a more strongly CG is prepared.  
Finally, our results were compared to the positive control jetPEI®, which showed 
approximately 32% gene expression compared to the highest transfection obtained by the GS 
alone (~ 8%) (Figure 5.5-8). We are still far away from the positive control and therefore, 
further studies are required to improve the transfection efficiency of CG/GS systems prior to 
introducing the Pluronics.  
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Figure 5.5-8: Transfection efficiency in % (expressed in terms of EGFP expression of live cells) (A), and 
cell viability in % (expressed in terms of dead cells stained by PI) (B) of the positive control (JetPEI) and 
GS/DNA complex in COS-7 cells . Positive control is significantly different than the highest transfection 
obtained with GS and DNA alone (***P<0.0001).  
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5.6 Summary 
Transfection efficiency and cell viability of cationic gelatin/Pluronic/DNA were tested in 
COS-7 cells. The results showed that cationic gelatin is unable to transfect the DNA, either in 
the presence or absence of Pluronics, in water, or in buffer. From the results, it appears that 
cholamine-modified gelatin nanoparticles are not able to transfect DNA, most likely due to 
aggregation of the complexes upon addition of DNA. It is clear that a different method of 
introducing cationic groups into the structure of gelatin is required in order to optimize the 
potential for gelatin as a transfection agent. Alternatively, small peptide sequences could be 
coupled to the amino acid side-chains to improve the targeting, to enhance the cellular 
uptake, or to induce the permeability of the cells, and combine such a gelatin polymer with 
the GS, which was able to transfect DNA. For such a strategy to be successful, a means of 
blocking the aggregation of the GS/gelatin/DNA complexes would be required, possibly 
utilizing a layer-by-layer formulation strategy, where the GS/gelatin/DNA complexes are 
stabilized by an additional component. Ultimately, further studies are required to understand 
the interaction of the gemini surfactant and the gelatin, which seems to be an antagonistic 
interaction, based on our results.  
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  Summary and Future Studies 
6.1 Summary 
Gelatin, as a natural polymer, is a promising agent for gene delivery due to several 
advantages that include biodegradability, biocompatibility, low cost, and the relative ease 
with which it can be functionalized. In this project, we hypothesized that gelatin-modified 
nanoparticles, in combination with the Pluronic block copolymers, could improve the 
transfection efficiency of DNA in COS-7 cells in vitro. The project started with the 
preparation of gelatin nanoparticles in Chapter 3 using the two-step desolvation method. The 
gelatin was then modified by adding a cationic agent (cholamine) in order to increase the 
positive charge, which is essential to interact with the DNA and the cellular membrane. 
Gelatin nanoparticles were successfully modified and characterized to confirm to the 
cationization. Cationic gelatin nanoparticles carry increased positive charge, with an average 
zeta potential of approximately 30 mV whereas unmodified gelatin nanoparticles have an 
average zeta potential of approximately 10 mV. SEM and TEM showed that the 
nanoparticles are spherical in nature, with an average diameter of ~100 nm. We also studied 
the characterizations of cationic gelatin and DNA in the presence and absence of Pluronics in 
terms of size and zeta potential in water. The results showed that cationic gelatin is able to 
complex the DNA by changing the negative charge of DNA to a positive charge at a ratio of 
1:20. At the same ratio, the size of DNA (~ 450 nm) decreased to 160 nm after adding CG 
indicating a successful complexation. Adding Pluronic to CG/DNA complex resulted in a 
small size (140-170 nm) with a positive charge for all formulations. The size and the charge 
of CG/DNA/Pluronic varied depending on the type and the concentration of each Pluronic. A 
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study on the effect of transfection complex CG/Pluronic/DNA on the model membranes was 
outlined in Chapter 4. The objective of that chapter was to understand the interaction of the 
transfection complexes, and their components, with the biological membranes. Two types of 
the model membrane were used: 1) DPPC-CHOL at the ratio of 3:1 (which mimics a healthy 
biological membrane); and 2) POPC-CHOL at the ratio of 4:1 (which mimics a cancerous 
cell membrane). DPPC-CHOL formed a more condensed monolayer compared to POPC-
CHOL. Interactions between DNA and the model membranes resulted in more condensed 
monolayers for both the DPPC-CHOL and POPC-CHOL systems, which were attributed to 
the electrostatic or the hydrophobic interactions. The addition of CG alone was then added to 
DPPC-CHOL. Due to both the electrostatic and the hydrophobic interactions, CG induced the 
fluidization of the membrane, which is important to enhance the permeability of a cellular 
membrane. The same effect was noted with Pluronic, either alone or in combination with 
CG, but to a lesser degree than CG. In terms of POPC-CHOL, not much change was noticed, 
neither with CG nor with Pluronics due to the fluidization of POPC-CHOL. Adding DNA 
induced the condensation of CG/DNA/Pluronic in both DPPC-CHOL and POPC-CHOL. 
These results indicate that CG/Pluronic/DNA complex was able to interact with the cellular 
membranes and enhanced their permeability. Further studies are required to fully understand 
the interaction between the CG, DNA, and the Pluronic.  
The transfection efficiency and cell viability of the CG/Pluronic/DNA complexes were 
evaluated in vitro in the COS-7 cell line. Despite the observations from Chapter 4, which 
suggested successful disruption of biological membranes, the use of CG as a transfection 
agent failed to show any gene expression, despite being attempted under several conditions 
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and after several optimizations. The most likely reason is that the cholamine, used to provide 
the additional cationic character to the gelatin polymer, was not able to provide a sufficient 
degree of cationic character to be able to both bind and condense DNA, and to passively 
target the cell membrane. Other possible reasons could include the size of the DNA; 
however, this can be discounted as the size of the CG/DNA complexes (Chapter 3) are in fact 
comparable in size to the gemini surfactant/DOPE/DNA complexes previously studied by 
our group and others (Foldvari, Badea et al. 2006, Wang, Kaur et al. 2013). Other factors 
could include batch effects in the gelatin (i.e., variation in amino acid sequences that can 
occur between batches), as well as the method of introducing cationic groups into the 
structure of gelatin. Transfection with the cationic gelatin based nanoparticles was only 
achieved upon addition of the 16-3-16 gemini surfactant to our formulation. Transfection 
levels achieved with gemini surfactant in combination with the cationic gelatin system was at 
significantly lower levels than observed for the GS/DOPE systems reported elsewhere in the 
literature, indicating that not only was cationic gelatin insufficient in being able to transfect 
DNA on its own, but also that its presence in fact likely shielded the overall positive charge 
of the nanoparticles, ultimately decreasing transfection efficiency. The addition of Pluronics 
appeared to have no effect, and it may be that in vivo studies are required to determine 
whether or not any benefit was obtained from the inclusion of Pluronics in our nanoparticle 
formulation.   
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6.2  Future Studies 
The first and most important step required before applying the following suggestion is to 
conduct a cellular trafficking study for the cholamine-modified gelatin nanoparticles. This 
research will help to understand if cholamine-modified gelatin nanoparticles are able to enter 
into the nucleus and whether or not DNA is able to dissociate from the nanoparticles, and 
whether or not it gets degraded; these are all possible alternative reasons for the observed low 
transfection. Following this study, many other experiments can be conducted in the future in 
order to design more effective vectors that are capable of delivering DNA into the cells. 
Firstly, there are many other cationic agents other than cholamine that can be used for gelatin 
modification. These include, but are not limited to spermine, spermidine, putrescine, and 
ethylenediamine. Spermine showed favourable results as a transfection agent in several 
studies in the literature (Hosseinkhani, Aoyama et al. 2002, Konat Zorzi, Contreras-Ruiz et 
al. 2011, Zorzi, Parraga et al. 2011, Zorzi, Parraga et al. 2015). Since cholamine was chosen 
based on previous studies, it is worth trying other cationic agents, as gelatin batches differ 
from one to another. Short, cationic amino acid sequences, such as polylysine, can also be 
readily coupled to gelatin to provide an alternative strategy for cationization. 
Secondly, gelatin nanoparticles were prepared using a two-step desolvation method. This 
method is simple and resulted in stable and homogenous nanoparticles. However, mixing 
DNA with gelatin nanoparticles might not form an effective and robust complex, as the DNA 
may readily detach from the surface of the nanoparticles, which could then result in the 
degradation of DNA through enzymatic degradation. Different methods can be used other 
than desolvation. For example, Zorzi et al. (Zorzi, Párraga et al. 2011) prepared cationic 
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gelatin nanoparticles using the ionic gelation technique for an ocular surface. In this 
technique, Zorzi and his colleagues used chondroitin sulfate (CS) and dextran sulfate (DS) to 
produce cationic gelatin. The cationized gelatin was then added to triphosphate (TPP) 
containing the plasmid and CS or DS.  One advantage of this method is the fact that no 
organic solvents such as acetone were used, in comparison to two-step desolvation (Zorzi, 
Parraga et al. 2011).  
Thirdly, the addition of PEG is important to protect the DNA from the reticuloendothelial 
system (RES) upon systemic administration. While Pluronics were used in our project to 
replace the function of PEG, it appears that the hydrophobic-hydrophobic interaction 
between Pluronic and gelatin decreased the effectiveness of the gelatin, which resulted in 
lower transfection efficiency. Since the interaction between gelatin and Pluronics is not 
completely understood, more studies are needed to understand this interaction before 
applying them to gelatin.   
Fourthly, gelatin is a weak transfection agent when used on its own. Since gelatin is easily 
modified, many targeting ligands can be applied in order to target specific cell types through 
the receptor-ligand interaction. The most common example of these ligands is the epidermal 
growth factor receptor (EGFR), which has been used with gelatin nanoparticles and showed 
higher transfection efficiency in several types of cancer. Another example of ligands includes 
folate receptor, which can be used alone, with gelatin, or in combination with PEG-gelatin 
nanoparticles.  
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Finally, gemini surfactant was used in the transfection experiments, and the results showed 
that the interaction of cationic gelatin and gemini surfactant resulted in aggregation. As a 
result, we are interested in further studying this interaction to understand the reasons for this 
aggregation. Although the results of monolayer study showed that there is no correlation with 
the transfection results of the cationic gelatin and the Pluronic, it might be helpful to use the 
monolayer study to understand the interaction between gemini surfactant and cationic gelatin. 
This understanding will help in developing and improving the effectiveness of either gelatin 
or gemini surfactant, or both, as the science is about a building of information.  
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